3 Stocks That Are Poised to Generate Outsized Returns
- In general, stocks generate outsized returns because the Street has been overly bearish on their outlook. Due to the Street's overdone high interest rate concerns, it's now unduly pessimistic about many growth equities with great futures.
- 11/10/2023
|
Bionano Genomics, Inc. (BNGO) Q3 2023 Earnings Call Transcript
- Bionano Genomics, Inc. (NASDAQ:BNGO ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants David Holmes - Investor Relations Erik Holmlin - Chief Executive Officer Gülsen Kama - Chief Financial Officer Conference Call Participants Michael Okunewitch - Maxim Group Sung Ji Nam - Scotiabank Jeffrey Cohen - Ladenburg Thalmann Operator Good day, and welcome to the Bionano's Third Quarter 2023 Earnings Conference Call. Today's conference is being recorded.
- 11/08/2023
|
Bionano to Report Third Quarter 2023 Financial Results and Host a Conference Call and Webcast on November 8, 2023
- SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Wednesday, November 8, 2023, at 4:30 p.m. Eastern Time to report financial results for the third quarter 2023 and to highlight recent corporate progress.
- 11/01/2023
|
3 Deeply Undervalued Growth Stocks
- One of the New York Yankees' most well-known players', Yogi Berra, famous for his strange, yet funny statements, used to say, “This is deja vu all over again.” That's how I feel about U.S. stocks at this point.
- 10/27/2023
|
Bionano Genomics, Inc. (BNGO) Upgraded to Buy: Here's What You Should Know
- Bionano Genomics, Inc. (BNGO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 09/21/2023
|
The 3 Best High-Risk, High-Reward Stocks to Buy Now: September 2023
- Due to a combination of worries about high-interest rates, China's decision to prevent some government employees from using Apple's (NASDAQ: AAPL ) iPhones at work, and the fact that September is historically a very bad month for equities. many high-risk, high-reward stocks have taken a beating recently.
- 09/11/2023
|
7 F-Rated Meme Stocks to Avoid Like the Plague
- Sometimes I really question why we're still talking about meme stocks. When will investors learn that the unpredictable nature of meme stocks nearly always makes them a bad investment choice?
- 09/04/2023
|
These Are the ONLY 3 Meme Stocks to Consider in August 2023
- Meme stocks feel like a relic of a bygone era. Indeed, all of the meme stocks that I can think of have been totally crushed since their heyday.
- 08/28/2023
|
Why Bionano Genomics Stock Tanked Today
- One of its top executives is departing. He will be replaced effective Sept.
- 08/14/2023
|
3 Top Short Squeeze Stocks for August 2023
- Short squeezes affect heavily shorted stocks when many sellers are forced to buy back the shares they shorted. That dynamic, in turn, causes the stock's price to soar, creating more purchases by short sellers and causing the process to continue.
- 08/10/2023
|
Bionano Genomics, Inc. (BNGO) Reports Q2 Loss, Tops Revenue Estimates
- Bionano Genomics, Inc. (BNGO) came out with a quarterly loss of $1.24 per share versus the Zacks Consensus Estimate of a loss of $0.90. This compares to loss of $1.10 per share a year ago.
- 08/09/2023
|
Bionano Genomics, Inc. (BNGO) Q2 2023 Earnings Call Transcript
- Bionano Genomics, Inc. (NASDAQ:BNGO ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants David Holmes - IR Erik Holmlin - CEO Chris Stewart - CFO Conference Call Participants Jason McCarthy - Maxim Group Mark Massaro - BTIG Sung Ji Nam - Scotiabank Daniel Hultberg - Oppenheimer Michael Okunewitch - Maxim Group Operator Good day, and welcome to the Bionano's Second Quarter 2023 Earnings Conference Call. Today's conference is being recorded.
- 08/09/2023
|
BNGO Stock Alert: Bionano Just Reverse Split Its Stock
- Bionano Genomics (NASDAQ: BNGO ) effected a 1-for-10 reverse stock split and announced that it will publish quarterly earnings on Aug. 9. Shares opened this morning at $4.73 each, a market capitalization of $1.49 billion.
- 08/07/2023
|
Bionano to Report Second Quarter 2023 Financial Results and Host a Conference Call and Webcast on August 9, 2023
- SAN DIEGO, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Wednesday, August 9, 2023, at 4:30 p.m. Eastern Time to report financial results for the second quarter 2023 and to highlight recent corporate progress.
- 08/02/2023
|
Looking for a Bargain? 3 Biotech Stocks to Buy That Are Down 20%-60% in 2023
- American drug makers can generate gigantic profits, pushing their stock prices to great heights. The pharmaceutical sector is lucrative in general around the globe, while the space is very profitable in America in particular.
- 08/01/2023
|
Best Penny Stocks To Buy Now? 6 Under $1 To Watch Now
- Today's penny stock market is brimming with high-volatility stocks. That especially relates to those that fall into the category of the cheapest penny stocks.
- 07/26/2023
|
3 Penny Stocks Under $1 To Watch Before August 2023
- Some of the most volatile penny stocks today are the cheapest. This idea of “cheap” is in the sense that prices are extremely low compared to other stocks.
- 07/21/2023
|
The 7 Best Growth Stocks to Buy in July
- This is a great time for investors to buy the best growth stocks. In addition to America's very strong macro trends, many companies have been reporting excellent results in the last several weeks.
- 07/05/2023
|
10 Top Penny Stocks To Watch Right Now For Under $1
- Welcome to the world of penny stocks. This is a corner of the stock market that piques interest and raises eyebrows in equal measure.
- 06/29/2023
|
7 Penny Stocks To Watch Right Now For Under $1
- Have you ever dreamt of uncovering a hidden gem in the stock market, something that could turn your modest investment into a jackpot? Welcome to the world of penny stocks.
- 06/27/2023
|
3 Penny Stocks with Multibagger Potential for the Second Half of 2023
- With investors looking for growth wherever they can find it, it's a good time to look at penny stocks to watch in 2023. Granted, penny stocks carry a higher risk than blue-chip stocks, but they also carry the potential for outsized returns.
- 06/26/2023
|
7 Healthcare Stocks to Make You the Millionaire Next Door
- Investing in healthcare stocks can be a wise decision for those looking to become wealthy in the long term. Some of the best healthcare stocks to buy are firms that are developing highly effective drugs for prevalent diseases for which there are no real effective treatments.
- 06/21/2023
|
Bionano to Present at the Healthcare Virtual Conference
- SAN DIEGO, June 21, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), today announced that the company will participate at the Healthcare Virtual Conference , presented by Maxim Group LLC and hosted by M-Vest. Erik Holmlin, Ph.D., Bionano's president and chief executive officer, is scheduled to present a company overview and fire-side chat discussion hosted by Michael Okunewitch, Senior Research Analyst at Maxim Group on Wednesday, June 21, 2023 at 12:30 pm ET.
- 06/21/2023
|
Hero or Zero? 3 High-Risk Penny Stocks to Make You Rich
- High-risk penny stocks have long tempted investors with the potential for significant returns. However, it is crucial to acknowledge the inherent risks associated with these speculative investments.
- 05/19/2023
|
3 Growth Stocks That Are Disrupting Their Industries in 2023
- Everyone who invests in growth stocks hopes that one of their holdings will become the next Netflix (NASDAQ: NFLX ), the next Amazon (NASDAQ: AMZN ), or the next Facebook. In other words, they're looking for names that can transform, or disrupt, entire sectors.
- 05/13/2023
|
Bionano Genomics, Inc. (BNGO) Reports Q1 Loss, Tops Revenue Estimates
- Bionano Genomics, Inc. (BNGO) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.11 per share a year ago.
- 05/09/2023
|
Better Gene Sequencing Stock: Illumina vs. Bionano Genomics
- Most biopharma players need access to gene sequencing services. Illumina is facing a handful of headwinds, but it's still the market leader.
- 05/06/2023
|
Top Penny Stocks To Buy? 4 Under $1 To Watch This Week
- Penny stocks to buy for under $1 but are they worth the risk this week? The post Top Penny Stocks To Buy?
- 04/26/2023
|
7 Growth Stocks With Huge Return Potential for Long-Term Investors
- Sooner or later, investors will stop fearing the “phantom recession,” i.e. the recession that really doesn't exist except in many economists' imaginations.
- 04/25/2023
|
10 Top Penny Stocks To Watch Under $1
- Penny stocks under $1 to watch this week. The post 10 Top Penny Stocks To Watch Under $1 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 04/25/2023
|
Using Technology to Trade Penny Stocks in 2023
- How to use technology to trade penny stocks right now The post Using Technology to Trade Penny Stocks in 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 04/25/2023
|
Why Shares of Bionano Genomics Are Up Monday
- Bionano says it expects another quarter of revenue growth. The company makes genomic testing equipment.
- 04/24/2023
|
Penny Stocks to Buy Now? 7 Under $1 To Watch This Week
- Penny stocks to watch under $1 this week. The post Penny Stocks to Buy Now?
- 04/24/2023
|
7 Stocks That Could Skyrocket in the Next 12 Months
- There are multiple signs that inflation is rolling over, while consumer spending remains strong and corporate earnings are beating expectations. Meanwhile, the so-called credit crunch many investors have feared really isn't materializing.
- 04/19/2023
|
Bionano Genomics: Dilution Coming
- Today, we circle back on an interesting diagnostic concern called Bionano Genomics, Inc. The company continues to build out its promising optical genome mapping capabilities. However, Bionano is also bleeding cash.
- 04/13/2023
|
3 Supercharged Growth Stocks With 662% to 741% Upside, According to Wall Street
- A difficult year for the stock market hasn't made Wall Street any less optimistic about equities. According to various analysts and pundits, three high-growth stocks have the necessary tailwinds to catapult higher by as much as 741%.
- 04/11/2023
|
The 3 Most Promising Penny Stocks to Buy in April
- A tried-and-true strategy for finding stocks to buy is to look in sectors of the economy that are growing or likely to. Although penny stocks carry more risk than higher-priced (and more well known) stocks, investors can use the same strategy to identify the most promising penny stocks.
- 04/07/2023
|
Buy This Magnificent Growth Stock Before It's Too Late
- Successful growth stocks don't stay under the market's radar for long. Bionano is getting the buy-in it needs from researchers and academic groups.
- 03/16/2023
|
Is Bionano Genomics a Risk Worth Taking at This Price?
- Bionano Genomics, Inc. (NASDAQ: BNGO) illustrates the risk and reward involved with many penny stocks. And that relationship is highlighted further with companies that are involved in emerging sectors like optical gene mapping.
- 03/13/2023
|
Bionano Genomics, Inc. (BNGO) Q4 2022 Earnings Call Transcript
- Bionano Genomics, Inc. (NASDAQ:BNGO ) Q4 2022 Earnings Conference Call March 9, 2023 4:30 PM ET Company Participants Amy Conrad - Investor Relations Erik Holmlin - Chief Executive Officer Chris Stewart - Chief Financial Officer Conference Call Participants Jeffrey Cohen - Ladenburg Sung Ji Nam - Scotiabank Michael Okunewitch - Maxim Group Mark Massaro - BTIG Operator Good day and welcome to the Bionano Fourth Quarter and Full Year 2022 Earnings Conference Call. [Operator Instructions] Please be advised that this conference is being recorded.
- 03/09/2023
|
Bionano Genomics, Inc. (BNGO) Reports Q4 Loss, Misses Revenue Estimates
- Bionano Genomics, Inc. (BNGO) delivered earnings and revenue surprises of -44.44% and 0.32%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 03/09/2023
|
Is Bionano Genomics Stock a Buy Now?
- Bionano Genomics is rapidly rolling out its genome mapping device. Its competitors don't have any product that serves the same purpose.
- 03/07/2023
|
This Growth Stock Is Down 38% and Wall Street Says It's Worth Buying Hand Over Fist
- With no recent stumbles and more growth on the way, buying shares now could be a smart move.
- 03/02/2023
|
7 Stocks to Buy on Weakness While You Can
- Despite the “hotter-than-expected” U.S. inflation data reported on Feb. 24, the fundamentals of the U.S. economy remain pretty strong. But don't take my word for it; listen to the CEO of JPMorgan, Jamie Dimon, who told CNBC on Feb. 23 that “The U.S. economy is doing quite well.
- 03/01/2023
|
Bionano to Present at the 43rd Annual Cowen Healthcare Conference
- SAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that company management will present at the 43rd Annual Cowen Healthcare Conference. Erik Holmlin, Ph.D., Bionano's president and chief executive officer, is scheduled to present a corporate overview on Monday, March 6th, 2023 at 1:30 pm ET.
- 02/27/2023
|
Is Bionano Genomics (BNGO) Stock Outpacing Its Medical Peers This Year?
- Here is how Bionano Genomics, Inc. (BNGO) and Amarin (AMRN) have performed compared to their sector so far this year.
- 02/13/2023
|
Why Bionano Genomics, Pacific Biosciences of California, and Sangamo Therapeutics Stocks Crumbled This Week
- These cutting-edge biotech companies quickly fell out of favor with investors this week.
- 02/10/2023
|
Are Medical Stocks Lagging Bionano Genomics (BNGO) This Year?
- Here is how Bionano Genomics, Inc. (BNGO) and Aziyo Biologics, Inc. (AZYO) have performed compared to their sector so far this year.
- 01/26/2023
|
3 Under-the-Radar Stocks With 590% to 772% Upside in 2023, According to Wall Street
- Select analysts expect these small-caps stocks to catapult higher in the new year.
- 01/23/2023
|
7 Must-Buy Nasdaq Stocks to Kick Off the First Quarter
- With the Nasdaq Composite having risen a robust 6% in the first two weeks of the New Year, it appears that the exchange, in line with my previous predictions, is well on its way to entering a bull market. Further, recent developments, including strong holiday-season retail sales growth and a month-over-month drop in December's Consumer Price Index, indicate that the Street's fears about the macro environment last year were tremendously overdone.
- 01/18/2023
|
Bionano Genomics (BNGO) Stock Pops on Promising Publication
- This could be a great day for medical science as well as for investors of Bionano Genomics (NASDAQ: BNGO ) stock. The biotech company just announced the publication of results concerning a proposed method to help detect breast cancer.
- 01/11/2023
|
Best Penny Stocks To Buy? 4 To Watch In January 2023
- 4 Biotech Penny Stocks To Watch, January 2023 The post Best Penny Stocks To Buy? 4 To Watch In January 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 01/11/2023
|
Is Bionano Genomics (BNGO) Stock Outpacing Its Medical Peers This Year?
- Here is how Bionano Genomics, Inc. (BNGO) and Exact Sciences (EXAS) have performed compared to their sector so far this year.
- 01/10/2023
|
The Top 7 Stocks to Watch in 2023
- A bull-bear battle is starting to materialize in the stock market, and I believe that the struggle will intensify in early 2023. Bears believe that we're heading for a steep recession and a horrible macro environment for stocks, and many of them are looking for unprofitable growth equities to short.
- 12/30/2022
|
This Innovative Growth Stock Could Double or More in 2023
- Investors have high expectations for Bionano Genomics, but they might not pan out.
- 12/22/2022
|
7 Drug Stocks That Will Soar in 2023
- Choosing the best drug stocks to buy can be dicey because drug stocks have disadvantages and advantages. On the negative side, you often have to wait many years for promising drugs to prove themselves in clinical trials.
- 12/22/2022
|
Bionano Genomics: Still Waiting For Genome Mapping Market To Reveal Itself
- Bionano Genomics, Inc. is an engaging company operating in the genome mapping space. The company generated $7.2m of revenues from 217 installed bases in Q322.
- 12/09/2022
|
3 Supercharged Growth Stocks With 393% to 1,153% Upside in 2023, According to Wall Street
- Select Wall Street analysts believe these fast-growing companies could skyrocket next year.
- 12/06/2022
|
3 Penny Stocks You Can Count On in This Uncertain Market
- Many people have trouble deciding where to invest their money. There are so many options, but it can be difficult to decide which one of them is the best.
- 11/25/2022
|
2 Penny Stocks That Could Make You Filthy Rich
- These low-priced equities could explode higher soon.
- 11/08/2022
|
3 Hypergrowth Stocks That Will Make You a Millionaire by 2027
- During the current earnings season, a few of the companies whose stocks I own delivered great third-quarter results. These results, along with their other achievements, shows that the firms' technologies are being widely-embraced by end users.
- 11/04/2022
|
7 Cheap Penny Stocks to Buy Before They Pop Off
- It may seem a little crazy to talk about finding cheap penny stocks to buy at this time. The economy is cooling, and even blue-chip stocks are struggling to gain traction.
- 11/04/2022
|
Bionano Genomics, Inc. (BNGO) Q3 2022 Earnings Call Transcript
- Bionano Genomics, Inc. (NASDAQ:BNGO ) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Amy Conrad - Investor Relations Erik Holmlin - Chief Executive Officer Christopher Stewart - Chief Financial Officer Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Operator Good day, and welcome to the Bionano Genomics Third Quarter 2022 Earnings Conference Call. Today's conference is being recorded.
- 11/03/2022
|
Bionano Genomics, Inc. (BNGO) Reports Q3 Loss, Tops Revenue Estimates
- Bionano Genomics, Inc. (BNGO) delivered earnings and revenue surprises of 8.33% and 7.78%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 11/03/2022
|
3 High-Octane Growth Stocks With 357% to 571% Upside, According to Wall Street
- Select analysts and pundits foresee game-changing upside from this fast-paced trio.
- 11/02/2022
|
Ranking 7 Top Tech Stocks to Buy From Biggest to Smallest
- It's true that the troika of Microsoft (NASDAQ: MSFT ), Alphabet (NASDAQ: GOOG , NASDAQ: GOOGL ), and Meta (NASDAQ: META ), much loved by the Street for the decade that ended in mid-2021, reported disappointing third-quarter results. Once viewed as beyond reproach by most, those three stocks are now being shunned and scorned by the “smart money.
- 10/28/2022
|
Bionano Genomics to Report Third Quarter 2022 Financial Results and Host a Conference Call and Webcast on November 3, 2022
- SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO) today announced that it will host a conference call and live webcast on Thursday, November 3, 2022 at 4:30 p.m. Eastern Time to report financial results for the third quarter 2022 and to highlight recent corporate progress.
- 10/27/2022
|
Wall Street Is Still Bullish on This Punished Growth Stock -- Is It a Buy?
- Bionano's stock price movements have little to do with its successes.
- 10/27/2022
|
What Is Going on With Bionano Genomics (BNGO) Stock Today?
- Bionano Genomics (NASDAQ: BNGO ) stock is rising higher on Wednesday after providing an update on its Long String VANTAGE product. This is a system that handles “automated, high throughput isolation of ultra high molecular weight (UHMW) DNA.
- 10/26/2022
|
Why Bionano Genomics' Shares Spiked 16.42% on Tuesday
- On an up day for Wall Street, the genome-mapping company may have benefited from a short squeeze.
- 10/25/2022
|
Why Is Bionano Genomics (BNGO) Stock Up 11% Today?
- Source: Dennis Diatel / Shutterstock.com Bionano Genomics (NASDAQ: BNGO ) stock is rising higher on Wednesday following the publication of a study related to optical genome mapping (OGM). According to the company, OGM was used to investigate a molecular subgroup of hepatocellular carcinoma ( HCC ).
- 10/05/2022
|
7 Penny Stocks to Buy Now for Extraordinary Gains
- If your initial instinct is that penny stocks represent extraordinarily risky ideas that feature little chance for success, you would be 100% correct. Clearly, conservative or risk-averse investors will find this subsegment of the market anathema to their approach.
- 09/21/2022
|
Bionano Genomics, Inc. (BNGO) Presents at H.C. Wainwright 24th Annual Global Investment Conference (Transcript)
- Bionano Genomics, Inc. (NASDAQ:BNGO ) H.C. Wainwright 24th Annual Global Investment Conference September 12, 2022 7:00 AM ET Company Participants Erik Holmlin - President and Chief Executive Officer Conference Call Participants Trevor Levy - H.C.
- 09/12/2022
|
Bionano Genomics to Participate at the H.C. Wainwright 24th Annual Global Investment Conference
- SAN DIEGO, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO) announced today that company management will participate virtually at the H.C. Wainwright 24th Annual Global Annual Global Investment Conference, taking place September 12-14, 2022. A pre-recorded presentation will be available on the Investor Resources page of the Company's website on Monday, September 12 at 7:00 am ET.
- 09/07/2022
|
These 2 Penny Stocks Have Tantalizing Growth Prospects
- Bionano Genomics and OrganiGram Holdings are both on track for long-term success.
- 08/30/2022
|
7 Hot Growth Stocks Poised to Triple by 2030
- This looks like a wonderful time for investors looking for hot growth stocks with very strong outlooks. I believe that the market is really starting to internalize the concept that Fed Chairman Jerome Powell is anything but super-hawkish on interest rates and that the economy is well-positioned for a “soft landing.
- 08/25/2022
|
7 Cheap Penny Stocks to Buy Before They Boom
- While virtually every financial advisor will steer you away from these picks, invariably, investors eventually gravitate toward cheap penny stocks to buy. Some might end their fascination with the topic at the investigatory stage.
- 08/19/2022
|
Why Is Bionano Genomics (BNGO) Stock Up 20% Today?
- Following brewing clinical momentum, shares of Bionano Genomics (NASDAQ: BNGO ) — a biotechnology firm specializing in nanoscale imaging and analytics — soared on Thursday. This came after the company announced the publication of a new study.
- 08/11/2022
|
Bionano Genomics, Inc. (BNGO) CEO Erik Holmlin on Q2 2022 Results - Earnings Call Transcript
- Bionano Genomics, Inc. (NASDAQ:BNGO ) Q2 2022 Results Conference Call August 4, 2022 4:30 PM ET Company Participants Amy Conrad - Investor Relations Erik Holmlin - Chief Executive Officer Christopher Stewart - Chief Financial Officer Conference Call Participants Michael Okunewitch - Maxim Group Operator Good day and welcome to the Bionano Genomics' Second Quarter 2022 Earnings Conference Call. Today's conference is being recorded.
- 08/04/2022
|
Bionano Genomics, Inc. (BNGO) Reports Q2 Loss, Tops Revenue Estimates
- Bionano Genomics, Inc. (BNGO) delivered earnings and revenue surprises of -10% and 7.58%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- 08/04/2022
|
Bionano Genomics ($BNGO) Generates Record Quarterly Revenue and Launches Version 6.2 of NxClinical
- Bionano Genomics, a pioneer of optical genome mapping solutions, has announced second quarter results that included 73% year-over-year revenue growth as well as a 24% increase in sales of its nanochannel array flowcells. The company also launched version 6.2 of its NxClinical software that includes integrated genomic scar analysis for homologous recombination deficiency.
- 08/04/2022
|
Bionano Genomics to Report Second Quarter 2022 Financial Results and Host a Conference Call and Webcast on August 4, 2022
- SAN DIEGO, July 28, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO) today announced that it will host a conference call and live webcast on Thursday, August 4th, 2022 at 4:30 p.m. Eastern Time to report financial results for the second quarter 2022 and to highlight recent corporate progress.
- 07/28/2022
|
What Are Penny Stocks & 3 To Buy According To Analysts In July
- Penny stocks to buy according to analysts. The post What Are Penny Stocks & 3 To Buy According To Analysts In July appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 07/18/2022
|
How to Find Penny Stocks to Buy in 2022
- Use these methods for finding penny stocks to buy in 2022 The post How to Find Penny Stocks to Buy in 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 07/09/2022
|
What to Know About Buying Penny Stocks on June 24th
- Here's what you need to know about trading penny stocks on June 24th The post What to Know About Buying Penny Stocks on June 24th appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 06/24/2022
|
I'm More Positive But Selling Puts Instead Of Buying Bionano Genomics
- My first article on Bionano Genomics was negative as the stock price did a meme-stock bounce far ahead of reality. I traded the stock below $1 hitting my short-term profit goal, then watched it spike into the teens, with some saying it would go to $100 a share.
- 06/23/2022
|
3 Stocks That Could Double in 2022
- Among the stocks that could double in the remainder of 2022 are Bionano , Rivian, and Plug Power. The outlook of all three is very strong.
- 06/08/2022
|
7 Cheap Biotech Stocks to Buy Now
- These biotech stocks are speculative, but could potentially blow up in the next couple of years with new treatments in the pipelines. The post 7 Cheap Biotech Stocks to Buy Now appeared first on InvestorPlace.
- 05/19/2022
|
What to Know About Buying Penny Stocks on May 19th
- Here's what you need to know about buying penny stocks today The post What to Know About Buying Penny Stocks on May 19th appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 05/19/2022
|
Bionano Genomics to Present at the 2022 H.C. Wainwright Global Investment Conference
- SAN DIEGO, May 17, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™ software, the leading solution for visualization, interpretation and reporting of genomic data, today announced its virtual participation in the 2022 H.C. Wainwright Global Investment Conference. Erik Holmlin, PhD, Bionano's president and chief executive officer, will present a company overview available for on-demand listening starting Tuesday, May 24, 2022, at 7:00 a.m. Eastern Time. Interested parties can register for the conference and view the presentation here: www.hcwevents.com/globalconference.
- 05/17/2022
|
Best Penny Stocks to Buy on Friday the 13th? 3 to Watch Today
- Why these three penny stocks are pushing up right now The post Best Penny Stocks to Buy on Friday the 13th? 3 to Watch Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 05/13/2022
|
Bionano Genomics, Inc. (BNGO) Reports Q1 Loss, Tops Revenue Estimates
- Bionano Genomics, Inc. (BNGO) delivered earnings and revenue surprises of -37.50% and 5.48%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 05/05/2022
|
Why Bionano Genomics Stock Is Risky, but a Good Bet
- The risks may be clear when it comes to Bionano Genomics and BNGO stock. However, investors should see this as a long-term play.
- 04/01/2022
|
Bionano Genomics, Inc. (BNGO) CEO Erik Holmlin at 2nd Annual Maxim Group Virtual Growth Conference (Transcript)
- Bionano Genomics, Inc. (BNGO) CEO Erik Holmlin at 2nd Annual Maxim Group Virtual Growth Conference (Transcript)
- 03/30/2022
|
Bionano Genomics to Present at the 2022 Maxim Virtual Growth Conference
- SAN DIEGO, March 23, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. ( BNGO ), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™ software, the leading solution for visualization, interpretation and reporting of genomic data, announced today that company management will present at the 2022 Maxim Virtual Growth Conference. Erik Holmlin, PhD, Bionano's president and chief executive officer, will participate in a fireside chat on Wednesday, March 30th, 2022 at 12:30 pm PT/3:30 pm ET.
- 03/23/2022
|
Bionano Genomics Stock Can Regain the Crucial $5 Level
- Bionano Genomics is working hard to address rare diseases, yet Wall Street doesn't see the value in BNGO stock -- but that could change soon. The post Bionano Genomics Stock Can Regain the Crucial $5 Level appeared first on InvestorPlace.
- 03/22/2022
|
How to Invest in Penny Stocks in 2022, 3 Strategies to Use
- Three strategies for trading penny stocks in 2022 The post How to Invest in Penny Stocks in 2022, 3 Strategies to Use appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 03/20/2022
|
Is Bionano Genomics a Buy?
- If you're willing to endure a slow start, it might be a great stock to own down the line.
- 03/19/2022
|
Bionano Genomics May Finally Offer a Reward for Your Risk
- BNGO stock has been a falling knife for the past year. But, with promising fundamentals and good tailwinds, now be the time to take a chance.
- 03/18/2022
|
Is the Death Cross a Positive for Penny Stocks? 3 to Watch
- Check these 3 penny stocks out after a recent death cross pattern The post Is the Death Cross a Positive for Penny Stocks? 3 to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 03/16/2022
|
3 Penny Stocks to Watch After the Best Trading Day in Almost 2 Years
- Here's three penny stocks to watch after a solid day of trading The post 3 Penny Stocks to Watch After the Best Trading Day in Almost 2 Years appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 03/09/2022
|
Bionano Genomics to Present at the 32nd Annual Oppenheimer Healthcare Conference
- SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™, a leading software solution for visualization, interpretation, and reporting of genomic data, announced today that company management will present virtually at the 32nd Annual Oppenheimer Healthcare Conference. Erik Holmlin, PhD, Bionano's president and chief executive officer, is scheduled to present a corporate overview on Tuesday, March 15th, 2022 at 5:40 am PT/8:40 am ET.
- 03/08/2022
|
Bionano Genomics to Present at the 42nd Annual Cowen Healthcare Conference
- SAN DIEGO, March 03, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClincial™, a leading software solution for visualization, interpretation and reporting of genomic data, announced today that company management will present virtually at the 42nd Annual Cowen Healthcare Conference. Erik Holmlin, Ph.D., Bionano's chief executive officer, is scheduled to present a corporate overview on Wednesday, March 9th, 2022 at 11:10 am PT/2:10 pm ET.
- 03/03/2022
|
Bionano Genomics' (BNGO) CEO Erik Holmlin on Q4 2021 Results - Earnings Call Transcript
- Bionano Genomics' (BNGO) CEO Erik Holmlin on Q4 2021 Results - Earnings Call Transcript
- 03/01/2022
|
Bionano Genomics to Report Fourth Quarter and Year End 2021 Financial Results and Host a Conference Call and Webcast on March 1st, 2022
- SAN DIEGO, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Tuesday, March 1st, 2022 at 4:30 p.m. Eastern Time to report financial results for the fourth quarter and year end 2021 and to highlight recent corporate progress.
- 02/22/2022
|
Bionano Stock Looks to Have a Monster Comeback in Its Future
- Bionano's Saphyr appears to be able to help doctors treat leukemia more effectively, and adoption of its device is growing rapidly. BNGO stock is a buy.
- 02/17/2022
|
Bionano Genomics to Present at the 2022 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
- SAN DIEGO, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™, the leading software solution for visualization, interpretation and reporting of genomic data, announced today that company management will present virtually at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference. Erik Holmlin, PhD, Bionano's president and chief executive officer, is scheduled to participate in a fireside chat on Wednesday, February 16th, 2022 at 2:30 pm ET. BTIG hosted events are intended for prospective and existing BTIG clients. To listen to the live event, please contact your BTIG representative with interest.
- 02/09/2022
|
Investors Have Cast Their ‘No' Votes Against Bionano Genomics
- A preliminary report from Bionano Genomics doesn't tell the full story and a lack of profitability will likely weigh on BNGO stock. The post Investors Have Cast Their ‘No' Votes Against Bionano Genomics appeared first on InvestorPlace.
- 02/07/2022
|
Bionano Is Not the Genomics Stock To Bet On
- Bionano's recent results are lackluster and point to more volatility ahead for BNGO stock. Best to just avoid this stock for now.
- 02/04/2022
|
Bionano Stock: The Delicate Balance Between Growth And Share Dilution
- Bionano Stock: The Delicate Balance Between Growth And Share Dilution
- 02/03/2022
|
4 Under-the-Radar Stocks With 319% to 645% Upside in 2022, According to Wall Street
- Select analysts and investment banks believe these little-known companies can skyrocket.
- 01/29/2022
|
Bionano Genomics Is Interesting as Genome Testing Scales Upwards
- BNGO Stock is a play in the burgeoning gene sequencing market at scale, not at home. That's worth understanding and potentially purchasing.
- 01/25/2022
|
BioNano Genomics Stock (BNGO): Why The Price Went Up Today
- The stock price of BioNano Genomics Inc (NASDAQ: BNGO) increased by 1.46% today. This is why it happened.
- 01/12/2022
|
Bionano Genomics Preliminary Q4, FY21 Revenue Exceed Expectations
- Bionano Genomics Inc (NASDAQ: BNGO) posted preliminary Q4 sales of $5.8 million - $6.2 million, +25% - 33% sequentially, up 45% - 55% Y/Y, and above the consensus of $5.44 million. FY21 revenue is expected to be $17.5 million - $17.9 million (consensus $17.13 million), more than doubled from FY20.
- 01/12/2022
|
7 of the Best Cheap Stocks Under $10 for 2022 to Buy Now
- These cheap stocks under $10 are poised to rally in the new, more friendly macro environment that's in place as 2022 unfolds. The post 7 of the Best Cheap Stocks Under $10 for 2022 to Buy Now appeared first on InvestorPlace.
- 01/06/2022
|
Bionano Genomics Stock Is a Low-Priced Bet on Sound Science
- Even though BNGO stock investors struggled in 2021, prepare for new price discovery as Bionano pushes the envelope in optical genome mapping. The post Bionano Genomics Stock Is a Low-Priced Bet on Sound Science appeared first on InvestorPlace.
- 01/03/2022
|
5 Buy-Rated Stocks Trading Under $10 With Huge 2022 New Year's Potential
- While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
- 01/01/2022
|
Best Penny Stocks to Buy in January 2022? 3 to Watch Next Week
- Add these penny stocks to your January 2022 watchlist The post Best Penny Stocks to Buy in January 2022? 3 to Watch Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 12/30/2021
|
The Critics Are Wrong About Bionano Stock
- The critics of Bionano are greatly underestimating the vast potential of Saphyr and of BNGO stock for long-term investors. The post The Critics Are Wrong About Bionano Stock appeared first on InvestorPlace.
- 12/27/2021
|
This Analyst's Saphyr Calculations Suggest Buying Bionano While It's Down
- If BNGO stock reaches Oppenheimer's price target, investors are looking at a return of more than 300%, plus long-term growth potential. The post This Analyst's Saphyr Calculations Suggest Buying Bionano While It's Down appeared first on InvestorPlace.
- 12/14/2021
|
Do Options Traders Know Something About Bionano (BNGO) Stock We Don't?
- Investors need to pay close attention to Bionano (BNGO) stock based on the movements in the options market lately.
- 12/10/2021
|
Bionano Genomics Proves Not Everything Genetic is Gold
- Bionano sells a $150,000 machine called Saphyr that does genetic mapping. It's a solid device, but its future remains in the future, as do BNGO stock fortunes.
- 12/01/2021
|
Wait for Bionano Stock to Fall Further Before Buying
- BNGO stock is breaking down following the latest earnings report, and there are no major catalysts to push shares up in the short term. The post Wait for Bionano Stock to Fall Further Before Buying appeared first on InvestorPlace.
- 11/23/2021
|
Bionano's Is on Track for Growth Thanks to Saphyr
- BNGO stock beats analyst forecasts yet again. Flush with cash and with Saphyr installations rising, this stock remains a high potential play.
- 11/19/2021
|
With Progress on Multiple Fronts, Bionano Genomics Stock Is Great Buy Here
- Bionano's acquisition of a software company makes Saphyr more attractive, and studies should result in insurers reimbursing those who use the system. BNGO stock is a buy.
- 11/12/2021
|
Bionano Genomics, Inc. (BNGO) CEO Erik Holmlin on Q3 2021 Results - Earnings Call Transcript
- Bionano Genomics, Inc. (BNGO) CEO Erik Holmlin on Q3 2021 Results - Earnings Call Transcript
- 11/05/2021
|
Bionano Genomics, Inc. (BNGO) Reports Q3 Loss, Tops Revenue Estimates
- Bionano Genomics, Inc. (BNGO) delivered earnings and revenue surprises of -16.67% and 16.38%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
- 11/04/2021
|
BNGO Stock: Why The Price Surged Today
- The stock price of BioNano Genomics Inc (NASDAQ: BNGO) increased by over 10% during intraday trading today. This is why it happened.
- 11/02/2021
|
Bionano Genomics to Report Third Quarter 2021 Financial Results and Host a Conference Call and Webcast on November 4, 2021
- SAN DIEGO, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Thursday, November 4, 2021 at 4:30 p.m. Eastern Time to report financial results for the third quarter ended September 30, 2021 and to highlight recent corporate progress.
- 10/28/2021
|
Bionano Genomics' Latest Software Business Acquisition Adds Immense Value
- BNGO stock isn't a darling of the markets at the moment, but Bionano continues to advance its stature in the optical genome mapping niche. The post Bionano Genomics' Latest Software Business Acquisition Adds Immense Value appeared first on InvestorPlace.
- 10/19/2021
|
Bionano Genomics Stock Looks Ready to Reward Patient Investors
- BNGO stock is down 25% since the beginning of the year. But as the company begins to deliver consistent revenue, a prudent investment may be rewarded.
- 10/18/2021
|
Bionano Genomics Announces American Society of Human Genetics Presentations Featuring Optical Genome Mapping for Genetic Disease and Cancer Research Applications
- SAN DIEGO, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), developer of the Saphyr® system that uses optical genome mapping (OGM) for the detection and analysis of structural variants (SVs), today announced the American Society of Human Genetics (ASHG) conference lineup of customer posters and presentations featuring OGM. The customer posters and presentations span genetic disease applications including amyotrophic lateral sclerosis (ALS) and postnatal, as well as cancer research applications including pediatric brain tumors and myelodysplastic syndromes (MDS). The ASHG conference is being held virtually this year and runs from Monday, October 18, 2021 to Friday, October 22, 2021.
- 10/15/2021
|
BNGO Stock: Why It Increased This Past Week
- The stock price of BioNano Genomics Inc (NASDAQ: BNGO) increased by over 6% this past week. This is why it happened.
- 10/13/2021
|
BNGO Stock: The Big Acquisition News Sending Bionano Genomics Soaring
- Bionano has just made a deal that will help it secure a spot among biotech companies riding the wave of the current boom. BNGO stock is up.
- 10/12/2021
|
Bionano Genomics to Acquire BioDiscovery, Furthering Bionano's Vision of Creating the Most Comprehensive Variant Analysis Platform in Genomics
- SAN DIEGO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO) today announced that it has entered into a definitive agreement to acquire BioDiscovery, Inc., a leading software company with best-in-class solutions for analysis, interpretation and reporting of genomics data. The transaction is expected to accelerate and broaden Bionano's market leadership in digital cytogenetics and comprehensive genome analysis. As a result of the transaction, Soheil Shams, PhD, Founder and Chief Executive Officer of BioDiscovery, will join Bionano's leadership team as Chief Informatics Officer.
- 10/12/2021
|
Groundbreaking Tech Makes Bionano Genomics Look Better Than Ever
- Off and on the price chart, Bionano Genomics could be the next big thing in genomics with multiple catalysts for BNGO stock. The post Groundbreaking Tech Makes Bionano Genomics Look Better Than Ever appeared first on InvestorPlace.
- 10/07/2021
|
BNGO Stock: What Is Driving Bionano Genomics Higher Today?
- Today, investors in Bionano Genomics and BNGO stock are cheering some positive clinical trial data around optical genome mapping. The post BNGO Stock: What Is Driving Bionano Genomics Higher Today?
- 09/30/2021
|
Largest Clinical Research Study to Date Evaluating Optical Genome Mapping for Analysis of Facioscapulohumeral Muscular Dystrophy Showed Concordance with Southern Blot and Reduced Turnaround Time by 50% as Compared to the Traditional Workflow
- SAN DIEGO, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO) today announced the publication of the largest clinical research study to date evaluating optical genome mapping (OGM) for facioscapulohumeral muscular dystrophy (FSHD), which concluded that OGM can be performed more quickly, accurately, and reproducibly than the current gold standard method of Southern blot analysis. This study, now available online before print in The Journal of Molecular Diagnostics, describes how OGM can be adopted as an alternative to Southern blot analysis for the identification of chromosomal abnormalities associated with FSHD, a neuromuscular disorder resulting in progressive weakness and atrophy of muscles.
- 09/29/2021
|
3 Top Tech Stocks to Buy on Weakness
- All three of these tech names, driven by very strong positive catalysts, should rally over the longer term, leading to high profits for investors. The post 3 Top Tech Stocks to Buy on Weakness appeared first on InvestorPlace.
- 09/21/2021
|
Bionano Genomics Remains Promising With Global Product Adoption
- BNGO stock has been stuck in a range, but its next move should be to the upside based on Bionano's breakthrough genome mapping system. The post Bionano Genomics Remains Promising With Global Product Adoption appeared first on InvestorPlace.
- 09/21/2021
|
4 Small-Cap Growth Stocks Expected to Increase Sales 707% to 9,406% by 2024
- These under-the-radar companies are expected to deliver jaw-dropping revenue growth over the next four years.
- 09/16/2021
|
NuProbe Global Adopts Bionano's Saphyr® System to Develop Products in Reproductive Health and Oncology Applications
- SAN DIEGO and SHANGHAI, China, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that NuProbe Global, a global molecular diagnostics company based in Shanghai, China and Houston, Texas, has adopted Bionano's Saphyr system for optical genome mapping (OGM) to integrate their Quantitative Amplicon Sequencing (QASeq) and Blocker Displacement Amplification (BDA) technologies for research and product development in the fields of reproductive health and oncology liquid biopsies.
- 09/07/2021
|
The Price Is Right for BioNano Genomics Given Saphyr's Potential
- With its Saphyr system seeing adoption ramp up, the long-term growth potential for BNGO stock is considerable. The post The Price Is Right for BioNano Genomics Given Saphyr's Potential appeared first on InvestorPlace.
- 08/30/2021
|
Bionano Stock Will Soar as the Company's Diagnostic System Catches On
- As more payors reimburse labs for using Bionano's Saphyr device, the company's financial results will improve, lifting BNGO stock. The post Bionano Stock Will Soar as the Company's Diagnostic System Catches On appeared first on InvestorPlace.
- 08/18/2021
|
Faster and Better Clinical Outcomes Make the Case for Bionano Genomics
- Bionano Genomics is mastering the science of genome mapping, while a reduced-price BNGO stock has a clear path forward for investors. The post Faster and Better Clinical Outcomes Make the Case for Bionano Genomics appeared first on InvestorPlace.
- 08/05/2021
|
Bionano Genomics' (BNGO) CEO Erik Holmlin on Q2 2021 Results - Earnings Call Transcript
- Bionano Genomics' (BNGO) CEO Erik Holmlin on Q2 2021 Results - Earnings Call Transcript
- 08/04/2021
|
Bionano Genomics, Inc. (BNGO) Reports Q2 Loss, Tops Revenue Estimates
- Bionano Genomics, Inc. (BNGO) delivered earnings and revenue surprises of -20.00% and 16.85%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 08/04/2021
|
Bionano Genomics Reports Second Quarter 2021 Financial Results and Highlights Recent Business Progress
- SAN DIEGO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) today reported financial results and business achievements for the second quarter ended June 30, 2021 and highlighted recent corporate updates.
- 08/04/2021
|
Bionano's Technology Is Interesting, But Its Earnings Are Uninspiring
- Bionano could become a decent testing company within its niche. However, BNGO stock has run far ahead of the company's fundamentals.
- 08/02/2021
|
Bionano (BNGO) to Report Q2 Earnings: What's in the Cards?
- Bionano Genomics (BNGO) is likely to provide updates on earnings and revenues when it reports second-quarter 2021 results.
- 07/29/2021
|
Bionano Genomics to Report Second Quarter 2021 Financial Results and Host a Conference Call and Webcast on August 4, 2021
- SAN DIEGO, July 28, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Wednesday, August 4, 2021 at 4:30 p.m. Eastern Time to report financial results for the second quarter ended June 30, 2021 and to highlight recent corporate progress.
- 07/28/2021
|
Weak Fundamentals Prove There Is No Reason to Buy Bionano Genomics
- Bionano Genomics is risky and its valuation does not justify its price. There is no compelling argument for a buy in BNGO stock.
- 07/23/2021
|
You'd Be Wrong to Paint Bionano Genomics Stock With the Meme-Stock Brush
- With Bionano's disruptive tool, Saphyr, poised to revolutionize the DNA analysis sector, investors should definitely look to buy BNGO stock on its recent dip. The post You'd Be Wrong to Paint Bionano Genomics Stock With the Meme-Stock Brush appeared first on InvestorPlace.
- 07/16/2021
|
Why Bionano Genomics, Invitae, and Opko Health Stocks Sank This Week
- The market's pessimism about these diagnostics stocks appeared unrelated to company-specific news.
- 07/16/2021
|
Bionano Genomics Announces Back-to-Back Publications in the American Journal of Human Genetics that Compare Optical Genome Mapping to Traditional Methods for Structural Variant Analysis in Inherited Genetic Disease and Hematological Malignancies
- SAN DIEGO, July 07, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that two peer-reviewed studies from world renowned scientists and clinicians from prestigious institutions in Europe including Radboud University Medical Center, Cochin Hospital in Paris, Hospices Civils in Lyon and the University Hospital of Clermont-Ferrand were published back-to-back in the American Journal of Human Genetics. One study analyzed the genomes of patients with inherited genetic disease and one study those of hematological malignancies. These seminal papers outline the utility of optical genome mapping (OGM) as a superior alternative to traditional methods for structural variant (SV) analysis. The results showed OGM was 100% concordant with findings from fluorescent in-situ hybridization (FISH), karyotype, and CNV-microarray when these traditional methods identified one or more pathogenic variants in samples from study subjects. Additionally, the higher resolution of OGM for all types of variants relative to traditional cytogenomics techniques allowed for a more precise characterization of breakpoints and the identification of genes they affect, the detection of smaller cancer-associated events that usually escape detection by traditional means, and the discovery of additional complexity of rearrangements. These publications will appear in the August print issue and are available online today at http://www.cell.com/ajhg
- 07/07/2021
|
Can These 5 Popular Stocks Double in 12 Months? Wall Street Thinks So
- Analysts for these sought-after companies foresee upside ranging from 105% to 144% over the next year.
- 07/07/2021
|
Bionano Genomics, Inc. (BNGO) Stock Sinks As Market Gains: What You Should Know
- Bionano Genomics, Inc. (BNGO) closed the most recent trading day at $6.72, moving -1.47% from the previous trading session.
- 07/02/2021
|
Bionano Genomics' Chief Medical Officer Dr. Alka Chaubey and Cancer Genomics Consortium President Dr. Yassmine Akkari to Present on Optical Genome Mapping (OGM) at the 2021 International Conference of the Board of Genetic Counseling India
- SAN DIEGO, July 02, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that Chief Medical Officer Dr. Alka Chaubey and current President of the Cancer Genomics Consortium Dr. Yassmine Akkari will present at the 6th Annual International Conference of the Board of Genetic Counseling India to be held virtually from July 2nd-4th 2021. Dr. Chaubey has been recognized to present as an invited speaker and will discuss how optical genome mapping (OGM) is enabling a revolution in cytogenetics during a session titled “Genetic Counseling in the Omics Era” on Saturday July 3rd at 9:25 am IST. Dr. Akkari will present her results using OGM for the genome analysis of Acute Myelogenous Leukemia (AML), and discuss how genetic counselors can introduce OGM to patients on July 3rd at 4:10 pm IST. Bionano Genomics is a Diamond Sponsor of the conference.
- 07/02/2021
|
Bionano Genomics to Present at the 2021 Ladenburg Thalmann Healthcare Conference
- SAN DIEGO, July 01, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that company management will present virtually at the 2021 Ladenburg Thalmann Healthcare Conference being held July 13-14, 2021. Erik Holmlin, PhD, Bionano's Chief Executive Officer, will present a company overview on July 13, 2021 at 4:30pm EDT.
- 07/01/2021
|
7 Hot Penny Stocks Analysts Like To Watch In 2021
- Current & Former Penny Stocks With High Marks From Analysts Right Now. The post 7 Hot Penny Stocks Analysts Like To Watch In 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 06/28/2021
|
Bionano Genomics Stock Has Short-Term Opportunities
- BNGO stock has established a reliable trading range. Even long-term investors can game it while they wait for their long-term reward.
- 06/28/2021
|
BNGO Stock: 2 Big Reasons Bionano Genomics Fans Should Be Cheering
- Bionano Genomics (BNGO) stock is getting a boost on Monday from a couple of new pieces of news that traders will want to know. The post BNGO Stock: 2 Big Reasons Bionano Genomics Fans Should Be Cheering appeared first on InvestorPlace.
- 06/28/2021
|
Wait for the Reddit Set to Sell Before Buying Bionano Stock
- With the "story" behind it still years in the making, take your time with BNGO stock. At some point, its meme stock investors will cash out, sending it back to more reasonable prices.
- 06/28/2021
|
Don't Wait Around for a Short Squeeze on Bionano Genomics Stock
- A popular trade on social media, BNGO stock has some bullish catalysts. But the primary spark, the short squeeze, might not fire.
- 06/28/2021
|
Geographic Expansion Enables Healthy Diagnosis for Bionano Genomics
- As Bionano's Saphyr system gains international recognition, BNGO stock deserves another chance at breaking through $15 and beyond. The post Geographic Expansion Enables Healthy Diagnosis for Bionano Genomics appeared first on InvestorPlace.
- 06/25/2021
|
Bionano Genomics, Inc. (BNGO) Stock Sinks As Market Gains: What You Should Know
- In the latest trading session, Bionano Genomics, Inc. (BNGO) closed at $7.15, marking a -1.38% move from the previous day.
- 06/24/2021
|
These 3 Meme Stocks Aren't as Risky as You May Think
- Solid revenue and earnings growth prospects of AMC, AHT and BNGO make them relatively safer bets despite being favorites of retail trades on the meme frenzy.
- 06/22/2021
|
The Owners of Bionano Stock Will Be Hurt by Dilution
- BNGO stock looks decent until you dive deeper and understand what's really going on. The shares' outlook isn't good.
- 06/22/2021
|
Bionano Genomics: Did Reddit Squirrels Find a Nut?
- Bionano Genomics offers a system called Saphyr that does optical genetic sequencing. If the technique floods the market, it could be a winner.
- 06/22/2021
|
Analyst Says Bionano Genomics Has 26% Upside: Should You Buy?
- BTIG analyst Sung Ji Nam recently initiated coverage of Bionano Genomics with a buy rating and a price target of $10. Is BNGO stock a buy?
- 06/21/2021
|
7 A-Rated Biotech Stocks to Buy Now
- Investors in search of long-term growth are increasingly choosing biotech stocks like BNTX stock and MRNA stock for their portfolios. The post 7 A-Rated Biotech Stocks to Buy Now appeared first on InvestorPlace.
- 06/15/2021
|
These 3 Stocks Will Make You Richer in 2021 (and Beyond)
- They're gaining this year. But the best may be yet to come.
- 06/14/2021
|
3 Meme Stocks to Buy Right Now!
- Meme stocks have a bad rap, but categorizing them like that could prove a big and costly mistake based on what these price charts are saying The post 3 Meme Stocks to Buy Right Now! appeared first on InvestorPlace.
- 06/10/2021
|
5 Healthcare Stocks to Buy for Their Game-Changing Potential
- These healthcare stocks are at the forefront of huge trends, including precision medicine and advances in diagnosis technologies. The post 5 Healthcare Stocks to Buy for Their Game-Changing Potential appeared first on InvestorPlace.
- 06/08/2021
|
Is It Too Late to Buy BioNano Genomics Stock?
- Does this gene-testing biotech company have value as more than a short-squeeze play?
- 06/08/2021
|
Why Bionano Genomics Stock Soared Today
- The genetic testing specialist is bolstering its leadership ranks.
- 06/07/2021
|
Hot Penny Stocks To Watch As AMC Stock Ignites Small Caps In June
- AMC stock ignites momentum in small cap penny stocks this month. The post Hot Penny Stocks To Watch As AMC Stock Ignites Small Caps In June appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 06/07/2021
|
BNGO Stock: The Big News Lifting Bionano Genomics This Morning
- BNGO stock is gaining on Monday thanks to r/WallStreetBets interest and a new corporate higher bringing a wealth of experience. The post BNGO Stock: The Big News Lifting Bionano Genomics This Morning appeared first on InvestorPlace.
- 06/07/2021
|
BNGO Stock Price: Over 12% Increase Pre-Market Explanation
- The stock price of BioNano Genomics Inc (NASDAQ: BNGO) increased by over 12% pre-market. This is why it happened.
- 06/07/2021
|
BNGO Stock: r/WallStreetBets Is Betting Big on a Short Squeeze for Bionano
- Today, amid an overall red day for meme stocks, BNGO stock has soared as speculation begins to build this could be the next short squeeze. The post BNGO Stock: r/WallStreetBets Is Betting Big on a Short Squeeze for Bionano appeared first on InvestorPlace.
- 06/04/2021
|
Bionano Stock Is Enticing on Strong Q1 Results and Saphyr's Progress
- Demand for Bionano's Saphyr tool is climbing, while new, potentially life-saving uses are being found for it. BNGO stock remains a buy.
- 06/03/2021
|
Could Bionano Genomics Be a Millionaire-Maker Stock?
- This provider of genome mapping tools is showing signs of exponential growth ahead.
- 05/29/2021
|
The Bear Case For Bionano Genomics Carries More Weight
- Bionano Genomics will have to show how its products are different than the competition if BNGO stock is to hold on to its recent gains. The post The Bear Case For Bionano Genomics Carries More Weight appeared first on InvestorPlace.
- 05/28/2021
|
Bionano Genomics, Inc. (BNGO) CEO Robert Holmlin Presents at Oppenheimer MedTech, Tools & Diagnostics Summit Conference (Transcript)
- Bionano Genomics, Inc. (BNGO) CEO Robert Holmlin Presents at Oppenheimer MedTech, Tools & Diagnostics Summit Conference (Transcript)
- 05/26/2021
|
Bionano Genomics to Present at the 2021 Oppenheimer MedTech, Tools & Diagnostic Summit
- SAN DIEGO, May 19, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that company management will present virtually at the Oppenheimer MedTech, Tools & Diagnostics Summit being held on May 26, 2021.
- 05/19/2021
|
5 Penny Stocks To Watch Right Now That Analysts Are Bullish On
- Penny stocks remain volatile but these analysts have a bright outlook on these The post 5 Penny Stocks To Watch Right Now That Analysts Are Bullish On appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 05/18/2021
|
5 Risky Stocks With 138% to 216% Upside, According to Wall Street
- Are these popular momentum stocks too cheap to ignore or blatant value traps?
- 05/17/2021
|
Bionano Genomics Just Can't Kick the Cash-Raising Bug With All Its Dilution
- Bionano Genomics can't kick the cash-raising bug. BNGO stock could fall to $1.85, its potential cash per share if it continues to raise cash.
- 05/14/2021
|
Why Bionano Genomics Stock Is Skyrocketing Today
- The company reported better-than-expected Q1 revenue growth.
- 05/14/2021
|
Why Bionano Genomics, CorMedix and Eloxx Are Moving Friday
- Bionano Genomics, Inc. (NASDAQ: BNGO), CorMedix Inc. (NASDAQ: CRMD) and Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) are among the health care movers Friday. Bionano Moves On Q1 Results: Bionano reported first-quarter revenues of $3.2 million, up 179% year-over-year.
- 05/14/2021
|
7 Reddit Penny Stocks Promising to Cure Cancer
- These seven risky Reddit penny stocks are in the biotech space and the business of developing cancer therapies and treatments. The post 7 Reddit Penny Stocks Promising to Cure Cancer appeared first on InvestorPlace.
- 05/14/2021
|
3 Penny Stocks That Gapped Up Big in Early Morning Trading
- These penny stocks gapped up big this morning; are they worth watching? The post 3 Penny Stocks That Gapped Up Big in Early Morning Trading appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 05/14/2021
|
Bionano Genomics (BNGO) Stock: Over 10% Increase Pre-Market Explanation
- The stock price of Bionano Genomics, Inc. (NASDAQ: BNGO) increased by over 10% pre-market. This is why it happened.
- 05/14/2021
|
Here's What Investors Liked About Bionano Genomics' Q1 Results
- The company delivered a pleasant surprise.
- 05/14/2021
|
Bionano Genomics, Inc. (BNGO) CEO Erik Holmlin on Q1 2021 Results - Earnings Call Transcript
- Bionano Genomics, Inc. (BNGO) CEO Erik Holmlin on Q1 2021 Results - Earnings Call Transcript
- 05/13/2021
|
Bionano Genomics, Inc. (BNGO) Reports Q1 Loss, Tops Revenue Estimates
- Bionano Genomics, Inc. (BNGO) delivered earnings and revenue surprises of 0.00% and 13.14%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
- 05/13/2021
|
Why BioNano Genomics Traded Higher Today
- BioNano Genomics Inc (NASDAQ:BNGO) shares traded higher by 6.9% to $4.41 after the company reported better-than-expected first-quarter sales results. Bionano Genomics reported quarterly sales of $3.2 million, which beat the analyst consensus estimate of $2.9 million.
- 05/13/2021
|
Bionano Genomics Reports First Quarter 2021 Financial Results and Highlights Recent Business Progress
- SAN DIEGO, May 13, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) today reported financial results and business achievements for the first quarter ended March 31, 2021 and highlighted recent corporate updates.
- 05/13/2021
|
Is Reddit Favorite BioNano Genomics About To Nosedive?
- BioNano Genomics (NASDAQ:BNGO) is testing an important support at the $5 level. If this support breaks, shares could make a rapid and large move lower.
- 05/13/2021
|
Is Bionano Genomics a Buy Ahead of Earnings?
- Don't mistake Bionano for just any Reddit stock. With its Q1 earnings looming, BNGO stock is attractively priced near its 2021 low.
- 05/12/2021
|
Implied Volatility Surging for Bionano Genomics (BNGO) Stock Options
- Investors need to pay close attention to Bionano Genomics (BNGO) stock based on the movements in the options market lately.
- 05/12/2021
|
5 Reddit Penny Stocks Seeing the Most Chatter Tuesday
- We're taking another dive into the world of penny stocks on Tuesday with a look at Reddit's most-talked-about for the day. The post 5 Reddit Penny Stocks Seeing the Most Chatter Tuesday appeared first on InvestorPlace.
- 05/11/2021
|
Bionano (BNGO) to Report Q1 Earnings: What's in the Cards?
- Bionano Genomics (BNGO) is expected to provide updates on its earnings and revenues when it reports first-quarter 2021 result.
- 05/10/2021
|
Don't Look Now, but Bionano Genomics May Be a Buy
- Bionano Genomics has lost a lot of supporters in recent months and some never came to the rescue, but a lifeline has been thrown to BNGO stock. The post Don't Look Now, but Bionano Genomics May Be a Buy appeared first on InvestorPlace.
- 05/07/2021
|
Don't Confuse Bionano Genomics As an Investment Right Now
- The science underlining BNGO stock is incredibly compelling. But that's not what the market actually cares about right now.
- 05/03/2021
|
Bionano Genomics Has Disappointed, but Its NHS Deal May Turn Things Around
- It's hard to reconcile the sell-off in BNGO stock with Bionano's progress in advancing the Saphyr system - but this presents an opportunity. The post Bionano Genomics Has Disappointed, but Its NHS Deal May Turn Things Around appeared first on InvestorPlace.
- 04/30/2021
|
Bionano Genomics, Inc. (BNGO) Dips More Than Broader Markets: What You Should Know
- Bionano Genomics, Inc. (BNGO) closed the most recent trading day at $6.97, moving -1.13% from the previous trading session.
- 04/28/2021
|
Why Cyclerion, Sol-Gel, Aldeyra, DermTech and Bionano Genomics Are Moving Today
- Cyclerion Therapeutics, Inc. (NASDAQ: CYCN), Sol-Gel Technologies Ltd. (NASDAQ: SLGL), Aldeyra Therapeutics, Inc. (NASDAQ: ALDX), DermTech, Inc. (NASDAQ: DMTK) and Bionano Genomics, Inc. (NASDAQ: BNGO) are among the biggest health care movers Tuesday.
- 04/27/2021
|
Why Ocugen, Zomedica, Naked Brand, and Other Reddit Stocks Soared Today
- The bulls are on parade.
- 04/26/2021
|
What's Going On With Bionano Genomics Stock Today?
- BioNano Genomics Inc (NASDAQ:BNGO) shares are trading higher by 19.5% at $7.36 Monday on continued strength following last week's publication of DNA replication data, a fundamental process of cell growth implicated in cancer that was previously hard to study in human genomes. Bionano Genomics is a life sciences instrumentation company in the genome analysis space.
- 04/26/2021
|
Bionano's UK Deal Is Huge for BNGO Stock
- Bionano's deal with the UK leaves the company well-positioned to make deals with many nations. Investors should buy BNGO stock.
- 04/23/2021
|
Is Bionano Genomics a Buy?
- Can you count on this company's novel gene diagnostic technology?
- 04/23/2021
|
2 Biopharma Stocks That Look Ready For A Bullish Reversal
- Ocugen Inc. (NASDAQ: OCGN) and Bionano Inc. (NASDAQ: BNGO) are two biopharma stocks moving higher Wednesday. Ocugen is moving after its partner Bharat Biotech announced positive study results, and Bionano gained ground after its system for optical genome mapping was adopted by two large labs in the U.K.'s National Health System.
- 04/21/2021
|
Why Bionano Genomics, Ocugen Are Rallying Today
- Bionano Genomics, Inc. (NASDAQ: BNGO) and Ocugen, Inc. (NASDAQ: OCGN) were among the early movers among biopharma stocks. Bionano Gains On Adoption of Genomic Mapping System By U.K. Labs: Bionano said its Saphyr system for optical genome mapping has been adopted by two large labs belonging to the National Heath System of the U.K.
- 04/21/2021
|
Should You Buy Bionano Genomics in April?
- This stock market mover's growth story is just beginning.
- 04/18/2021
|
Why Bionano Genomics Stock Is Tumbling Today
- No news; just run-of-the-mill volatility.
- 04/16/2021
|
Bionano Genomics Stock Is Too Wild for Its Own Good
- BNGO stock has seen too much action without fundamental justification. It makes a better speculative bet than an investment.
- 04/09/2021
|
Bionano Genomics Stock Has Huge Potential, But It's Very Risky
- BNGO stock is a play on a potentially disruptive technology. But investors can't forget that most potentially disruptive technologies fail.
- 04/09/2021
|
Bionano Genomics Announces Presentations on Optical Genome Mapping at the American Association for Cancer Research (AACR) Annual Meeting 2021
- SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that multiple studies on the detection of structural variants using Bionano's optical genome mapping, including a Spotlight Presentation, will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2021, which is being held in a virtual format April 10-15, 2021.
- 04/07/2021
|
Has Bionano Genomics (BNGO) Outpaced Other Medical Stocks This Year?
- Is (BNGO) Outperforming Other Medical Stocks This Year?
- 04/06/2021
|
Bionano Will Eventually Return to Earth Due to Its Weak Fundamentals
- Massive dilution, sluggish sales, and ballooning expenses will keep most away from BNGO stock despite its positive attributes. The post Bionano Will Eventually Return to Earth Due to Its Weak Fundamentals appeared first on InvestorPlace.
- 04/05/2021
|
The Recent Pullback in Bionano Genomics Is a Major Buying Opportunity
- BNGO stock has been beaten down as of late, but it presents a great buying opportunity to invest in the emerging life sciences player. The post The Recent Pullback in Bionano Genomics Is a Major Buying Opportunity appeared first on InvestorPlace.
- 04/02/2021
|
This Is When Bionano Genomics Becomes a Buy
- It may have the goods longer term, but a profitable position in BNGO stock in 2021 is tied to the price chart and maybe Ark Invest. The post This Is When Bionano Genomics Becomes a Buy appeared first on InvestorPlace.
- 04/02/2021
|
5 High-Flying Stocks That Turned $200,000 Into More Than $1 Million in 3 Months
- These stocks have been unstoppable since late December -- but will they stay that way?
- 03/27/2021
|
BNGO Stock: 9 Reasons Why Bionano Genomics Shares Are Getting a Boost Today
- Bionano Genomics (BNGO) stock is on the rise Wednesday as investors react to news announced by the company after markets closed on Tuesday. The post BNGO Stock: 9 Reasons Why Bionano Genomics Shares Are Getting a Boost Today appeared first on InvestorPlace.
- 03/24/2021
|
Why Investors Liked Bionano Genomics' Q4 Results
- The genomic analysis systems maker beat expectations and looks for a big jump in its installed base this year.
- 03/24/2021
|
Bionano Genomics, Inc. (BNGO) CEO Erik Holmlin on Q4 2020 Results - Earnings Call Transcript
- Bionano Genomics, Inc. (BNGO) CEO Erik Holmlin on Q4 2020 Results - Earnings Call Transcript
- 03/23/2021
|
Bionano Genomics: Q4 Earnings Insights
- Shares of Bionano Genomics (NASDAQ:BNGO) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 82.61% year over year to ($0.04), which beat the estimate of ($0.05).
- 03/23/2021
|
Bionano Genomics Announces Financial Results for the Three and Twelve Months Ended December 31, 2020 and Highlights Recent Corporate Updates
- -Solidified Financial Position Raising Approximately $335 Million in Q1 2021
- 03/23/2021
|
10 Reddit Penny Stocks Seeing the Most Chatter Today
- Reddit penny stocks continue to be of interest to risky investors and InvestorPlace is looking at the top ones for Monday. The post 10 Reddit Penny Stocks Seeing the Most Chatter Today appeared first on InvestorPlace.
- 03/22/2021
|
There's No Need to Chase Bubbly Bionano Genomics Stock
- A single study launched an epic rally in BNGO stock. But the company still has much to prove, and 3,400% gains don't price in the risks.
- 03/22/2021
|
Earnings Preview: Bionano Genomics
- Bionano Genomics (NASDAQ:BNGO) announces its next round of earnings this Tuesday, March 23. Here is Benzinga's everything-that-matters guide for this Tuesday's Q4 earnings announcement.
- 03/22/2021
|
BioNano Genomics Is About the Future, Not the Present
- BioNano may cause great disruption in the field of genetics. However, the payoff for investing in BNGO stock is likely to be years away.
- 03/22/2021
|
7 Earnings Reports to Watch Next Week
- Several noteworthy names are making their earnings reports next week. Here are some of the most interesting ones for investors to watch.
- 03/19/2021
|
Bionano Genomics: Recent Pullback A Strong Buy Opportunity
- Bionano Genomics, Inc. offers exposure to exciting high-growth themes like genomics and personalized medicine. BNGO offers a competitive product in the cytogenetics space that greatly reduces the inherent time and capital costs of genomics research.
- 03/19/2021
|
BioNano Genomics Will Likely Be Volatile Prior to Q4 Earnings
- Those investors bullish on genomics might want to analyze the Q4 results of BNGO stock The post BioNano Genomics Will Likely Be Volatile Prior to Q4 Earnings appeared first on InvestorPlace. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG It doesn't matter if you have $500 in savings or $5 million.
- 03/16/2021
|
Even Below the $10 Mark There Are Way Better Buys Than BioNano Genomics
- The risk-to-reward proposition has recently gotten a lot better for investors considering BNGO stock. Is it a buy for single digits?
- 03/16/2021
|
BioNano Genomics Is an Excellent Lesson in Technical Analysis
- Technically, BNGO stock appeared on the verge of a robust breakout move but with shares tumbling instead, it's time to reassess the overall picture. The post BioNano Genomics Is an Excellent Lesson in Technical Analysis appeared first on InvestorPlace.
- 03/15/2021
|
Bionano Genomics to Present at Several Upcoming Investor Conferences
- SAN DIEGO, March 15, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that company management will present virtually at the following investor conferences:
- 03/15/2021
|
Bionano Genomics, Inc. (BNGO) Stock Sinks As Market Gains: What You Should Know
- In the latest trading session, Bionano Genomics, Inc. (BNGO) closed at $9.38, marking a -1.57% move from the previous day.
- 03/12/2021
|
Bionano Genomics Presented at H.C. Wainwright Global Life Sciences Conference
- SAN DIEGO, March 10, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that company management presented virtually at the H.C. Wainwright Global Life Sciences Conference, which took place March 9-10, 2021. The presentation by Bionano CEO Dr. Erik Holmlin is available on-demand through the H.C. Wainwright conference portal and the Events page in the Investors section of Bionano's website at https://ir.bionanogenomics.com/. It will be archived on Bionano's website for 30 days following the event.
- 03/10/2021
|
Bionano Genomics to Report Fourth Quarter and Year End 2020 Financial Results and Host a Conference Call and Webcast on March 23rd, 2021
- SAN DIEGO, March 09, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Tuesday, March 23rd, 2021 at 4:30 p.m. Eastern Time to report financial results for the fourth quarter and year end 2020 and to highlight recent corporate progress.
- 03/09/2021
|
Implied Volatility Surging for Bionano Genomics (BNGO) Stock Options
- Investors need to pay close attention to Bionano Genomics (BNGO) stock based on the movements in the options market lately.
- 03/05/2021
|
Why Bionano Genomics (BNGO) Might Surprise This Earnings Season
- Bionano Genomics (BNGO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 03/05/2021
|
Lofty Expectations Are Already Priced Into Bionano Genomics
- BNGO stock is on the high side right now, especially since it will likely take time for the company's system to get traction. The post Lofty Expectations Are Already Priced Into Bionano Genomics appeared first on InvestorPlace.
- 03/04/2021
|
Bionano Customer Praxis Genomics Receives DEX Z-Codes from Palmetto for their Whole Genome Analysis LDT on Saphyr
- SAN DIEGO, March 03, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that Praxis Genomics, LLC received DEX Z-codes from Palmetto MolDX for its entire testing menu of laboratory developed tests (LDTs) based on Saphyr. The DEX Z-Code modifier is a unique 5-character alpha-numeric code associated with certain molecular diagnostics tests and is typically used by certain payers as an adjunct to non-specific CPT codes when no specific CPT code applies. The code, submitted on a claim along with a particular CPT code provides greater clarity to help payers and physicians understand which test is being ordered, performed and billed. The process removes the need for the provider to submit large amounts of additional information with every claim and can expedite claim payment. The assignment of DEX Z-codes to Praxis's menu of Saphyr-based LDTs is potentially a major step forward in the coding and eventual coverage of Saphyr-based tests.
- 03/03/2021
|
Bionano Genomics Would Have Been a Great Find Months Ago
- BNGO stock shot up massively in the past few months. Now isn't the time to invest as the company must first prove its technology sells.
- 03/02/2021
|
Bionano Genomics to Present at the Cowen 41st Annual Health Care Conference
- SAN DIEGO, March 02, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that company management will present virtually at the Cowen 41st Annual Health Care Conference. Erik Holmlin, PhD, Bionano's Chief Executive Officer, is scheduled to present on Thursday, March 4, 2021 at 2:10 pm EST.
- 03/02/2021
|
Bionano Genomics, Inc. (BNGO) Gains But Lags Market: What You Should Know
- Bionano Genomics, Inc. (BNGO) closed at $9.84 in the latest trading session, marking a +1.13% move from the prior day.
- 03/01/2021
|
Bionano to be Featured at AGBT 2021 with Presentations of Scientific Discoveries made with Saphyr in Psychiatric Disorders and Cancer
- SAN DIEGO, March 01, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that the 2021 Advances in Genome Biology and Technology (AGBT) meeting will feature presentations from scientists at leading research institutes and hospitals including Boston Children's Hospital, Harvard Medical School, Tel Aviv University and the company describing their work with the Saphyr System for optical genome mapping (OGM) in psychiatric disorders and cancer. AGBT will be held virtually at https://www.agbt.org/ March 1-3. Bionano's optical genome mapping technology will be discussed in poster presentations and plenary talks on AGBT's main agenda. Additionally, Bionano will host a live interview with Bionano CEO Dr. Erik Holmlin and CMO Dr. Alka Chaubey conducted by Theral Timpson, Host, Producer and Co-Founder of Mendelspod as part of the official conference program. The recording of the interview will be released on Thursday, March 4 as a regular episode of Mendelspod, the leading podcast covering the genomics industry.
- 03/01/2021
|
Bionano's Saphyr Data Prove Essential in Creating the Most Comprehensive, Ethnically Diverse Collection of Genome Variation Ever Completed
- Article published in Science reveals that optical genome mapping uniquely makes thousands of large structural variant calls Article published in Science reveals that optical genome mapping uniquely makes thousands of large structural variant calls
- 02/25/2021
|
Investors Should Have BNGO Stock on Their Long-Term Watch List
- BNGO Stock has alot of potential for growth in the long term but its risks currently limit its attractiveness as an investment The post Investors Should Have BNGO Stock on Their Long-Term Watch List appeared first on InvestorPlace. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG Top Stock Picker Reveals His Next Potential Winner It doesn't matter if you have $500 in savings or $5 million.
- 02/25/2021
|
BNGO Stock: What to Know as Bionano Genomics Drops 15% Today
- BNGO stock is on the move today without any real company news. Here's what you should know about Bionano Genomics now.
- 02/23/2021
|
2 Stocks that Ark Invest loves for 2021
- Let's take a look at two companies that Wood has her eye on and has recently added to Ark's large portfolio of funds.
- 02/22/2021
|
Leverage the Power of Genetics Tech With Bionano Genomics
- BNGO stock is an investment in the future of gene discovery and therapy as Bionano pushes the boundaries of optical genome mapping tech. The post Leverage the Power of Genetics Tech With Bionano Genomics appeared first on InvestorPlace.
- 02/22/2021
|
Bionano (BNGO) to Report Q4 Earnings: What's in the Offing?
- Bionano (BNGO) will provide updates on its revenues and earnings when it reports fourth-quarter and full-year 2020 results.
- 02/22/2021
|
Bionano Publishes Method for Identifying Genes Likely to Cause Neurological Diseases Based on a Model Developed by Lineagen to Improve Interpretation of Variants of Unknown Significance
- Proprietary scoring algorithm may help identify novel genes for nervous system disorders; applications include patient testing and eventually discovery research with Saphyr Proprietary scoring algorithm may help identify novel genes for nervous system disorders; applications include patient testing and eventually discovery research with Saphyr
- 02/22/2021
|
Is It Too Late to Buy Bionano Genomics Stock?
|
BNGO Stock Price Increases Over 11%: Why It Happened
- The stock price of BioNano Genomics Inc (NASDAQ: BNGO) is trading at over 11% as of 3:27 PM ET. This is why it happened.
- 02/16/2021
|
BioNano Genomics' Next Double Won't Come Easily
- Bionano Genomics makes Saphyr, a genome imaging tool. With BNGO stock doubling over the past month, investors should give the company a look.
- 02/16/2021
|
Is BioNano Genomics Stock a Buy?
- If you're bullish on genomics, you should be bullish on this stock.
- 02/13/2021
|
BNGO Stock Price Increased 17.09%: Why It Happened
- The stock price of BioNano Genomics Inc (NASDAQ: BNGO) has increased by 17.09% today. This is why it happened.
- 02/12/2021
|
Why Bionano Genomics Stock Surged Today
- The genetic testing specialist could access a major new market.
- 02/12/2021
|
4 Top Stock Trades for Tuesday: MJ, NWL, CIIC, BNGO
- The Alternative Harvest ETF, CIIC Merger, Newell Brands and Bionano Genomics were our top stock trades for Tuesday. Let's look at the charts.
- 02/12/2021
|
BNGO Stock: Why Bionano Genomics Shares Rallied 17% Today
- BNGO stock has continued to shoot higher today on a string of good news that has investors excited about this company's long-term prospects. The post BNGO Stock: Why Bionano Genomics Shares Rallied 17% Today appeared first on InvestorPlace.
- 02/12/2021
|
Bionano Genomics Has a Story That Investors Should Get Behind
- BNGO stock is up 280% this year as its story begins to unfold. The stock may cool off, but it looks like there are many chapters to come for the firm.
- 02/12/2021
|
Bionano Genomics to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
- SAN DIEGO, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that company management will present virtually at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference. Erik Holmlin, PhD, Bionano's Chief Executive Officer, is scheduled to participate in a fireside chat on Thursday, February 18, 2021 at 1:30 pm PST.
- 02/11/2021
|
BioNano Genomics Is in a Perfect Bull-Bear Tug of War
- Among all the biotech pivots toward the novel coronavirus, BNGO stock represents one of the most sensible. But does that mean shares are a buy?
- 02/10/2021
|
Bionano Genomics, Inc. (BNGO) Gains As Market Dips: What You Should Know
- Bionano Genomics, Inc. (BNGO) closed at $11.80 in the latest trading session, marking a +1.29% move from the prior day.
- 02/09/2021
|
The Sequence to More Highs is Unfolding in BNGO Stock Today
- A dazzling BNGO stock has flown under the radar in 2021, but don't expect shares of this newly-minted mid-cap to remain a secret. The post The Sequence to More Highs is Unfolding in BNGO Stock Today appeared first on InvestorPlace.
- 02/09/2021
|
Largest Hospital Diagnostic Lab in Canada Pilots Bionano's Saphyr; Seeking to Convert 30-Year-Old Workflow Based on Multiple Technologies Into a Single, High-Resolution Assay to Transform Cancer Diagnosis
- SAN DIEGO, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), announced today that its Saphyr system is being piloted by the University Health Network's (UHN) Laboratory Medicine Program (LMP) in Toronto. The LMP is the largest hospital diagnostic laboratory in Canada and one of the largest in the world, performing 25 million tests per year and serving 1,300 patients per day. UHN's Cancer Cytogenetics Laboratory led by Dr. Adam Smith plans to use the Bionano Saphyr system to test its ability to streamline cancer diagnostic techniques, improve detection of abnormalities and reduce complexity and costs.
- 02/09/2021
|
3 Stocks That Turned $200,000 Into $1 Million (or More) in 3 Months
- These high-flying stocks have been moneymakers since early November.
- 02/06/2021
|
Presentation Recordings from Bionano's Next-Generation Cytogenomics Symposium, its Most Attended Event to Date, Now Available Online
- SAN DIEGO, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced that presentation recordings from its 5-day Next-Generation Cytogenomics Symposium, which took place from January 11 to 15 and featured 33 presentations by Saphyr users, are now available online on the company's website and its YouTube page. This event was by far its highest attended to date, with more than 15,500 session registrations and more than 6,400 session views from around the world. With the presentation recordings now available online, the impact of the event can continue to grow and expand awareness of Bionano Genomics and its Saphyr system for optical genome mapping and structural variation analysis.
- 02/05/2021
|
Bionano Genomics, Inc. (BNGO) Stock Sinks As Market Gains: What You Should Know
- Bionano Genomics, Inc. (BNGO) closed at $11.85 in the latest trading session, marking a -1.41% move from the prior day.
- 02/03/2021
|
BioNano Genomics Takes Advantage of a Spike
- Bionano Genomics takes advantage of a spike to sell shares at highs. Cash likely represents about 19% of the BNGO stock market capitalization as a result of two capital raises.
- 02/03/2021
|
Why Mustang Bio, Phathom Pharma And More Are Moving Today
- Mustang Bio (NASDAQ: MBIO) shares are trading higher after the company announced the FDA has lifted the clinical hold for its pivotal phase 2 MB-107 clinical trial. The company plans to enroll the first patient in the second quarter of 2021.
- 02/02/2021
|
Dr. Gordana Raca from Children's Hospital Los Angeles Presents Findings That Show Saphyr Detects Druggable Gene Fusions in Pediatric Acute Leukemias that NGS and Cytogenetics Missed
- SAN DIEGO, Jan. 29, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced a presentation by the Director of the Clinical Cytogenomics Laboratory of Children's Hospital Los Angeles, Dr. Gordana Raca, in which she reported on the performance of optical genome mapping (OGM) for the clinical analysis of pediatric acute leukemias. She demonstrated how OGM with Saphyr detected clinically important structural variants (SVs) that can alter patient care and treatment decisions. These SVs were not detected when the samples were evaluated with a combination of next-generation sequencing (NGS) and three cytogenetic methods that are the standard of care in leukemia testing today. She concluded that OGM would be advantageous in clinical testing because it detects all types of SVs but with better precision, higher resolution and better sensitivity than traditional methods, including next generation sequencing (NGS).
- 01/29/2021
|
Should You Buy Bionano Genomics Stock?
- This high-flying stock is already one of the biggest winners in the new year.
- 01/27/2021
|
Bionano Significantly Reduces Analysis Cost and Time to Actionable Results with Update to its Cloud Compute
- Addition of Microsoft Azure as a High-Performance Computing provider reduces compute cost for genetic disease analysis by more than 50%, compute time by 30% Addition of Microsoft Azure as a High-Performance Computing provider reduces compute cost for genetic disease analysis by more than 50%, compute time by 30%
- 01/26/2021
|
3 Electric Stocks That Turned $100,000 Into $1 Million in 6 Months
- These popular companies have rallied between 1,000% and 2,400% since late July.
- 01/26/2021
|
Why Bionano Genomics Stock Rocketed More Than 28% Today
- Analysts are growing more bullish on the genetic testing specialist's growth potential.
- 01/25/2021
|
BNGO Stock Price Increases Over 12% Pre-Market: Why It Happened
- The stock price of BioNano Genomics Inc (NASDAQ: BNGO) increased by over 12% pre-market as of 8:26 AM. This is why it happened.
- 01/25/2021
|
Bionano Genomics Announces Closing of $230 Million Underwritten Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
- SAN DIEGO, Jan. 25, 2021 (GLOBE NEWSWIRE) -- BIONANO GENOMICS, INC. (Nasdaq: BNGO), announced today the closing of its previously announced underwritten public offering of 38,333,352 shares of its common stock, including 5,000,002 shares sold pursuant to the underwriters' exercise in full of their option to purchase additional shares, at a price to the public of $6.00 per share. The gross proceeds to Bionano from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $230 million.
- 01/25/2021
|
Why Bionano Genomics Stock Popped Today
- A Wall Street analyst's target-price hike may have had something to do with it.
- 01/22/2021
|
Why Bionano Has Tremendous Potential
- Bionano's products facilitate research into many diseases and the development of new treatments. Investors should buy BNGO stock.
- 01/22/2021
|
Why Bionano Genomics Stock Is Down Today
- The biotech's stock sales are alarming investors.
- 01/20/2021
|
UPDATE: Bionano Genomics prices $200 million underwritten stock offering at a discount of $6 a share
- Bionano Genomics Inc. priced a $200 million underwritten stock offering announced late Tuesday at a discount of $6 a share, selling 33.3 million shares. The stock closed Tuesday at an alltime high of $9.14.
- 01/20/2021
|
Bionano Genomics Announces Pricing of $200 Million Underwritten Public Offering of Common Stock
- SAN DIEGO, Jan. 20, 2021 (GLOBE NEWSWIRE) -- BIONANO GENOMICS, INC. (Nasdaq: BNGO), announced today the pricing of its previously announced underwritten public offering of 33,333,350 shares of its common stock at a price to the public of $6.00 per share. The gross proceeds to Bionano from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $200 million. In addition, Bionano has granted the underwriters a 30-day option to purchase up to an additional 5,000,002 shares of common stock at the public offering price, less underwriting discounts and commissions, to cover over-allotments, if any. All of the shares in the offering are to be sold by Bionano. The offering is expected to close on January 22, 2021, subject to customary closing conditions.
- 01/20/2021
|
Why Bionano Genomics Stock Surged Today and Then Plunged in After-Hours Trading
- The genome testing company's investors endured a volatile day.
- 01/19/2021
|
Bionano Genomics to sell more shares, stock falls
- Bionano Genomics Inc. on Tuesday announced its second share sale in less than a month amid an unexplained spike in its price and volume, sending shares down in after-hours trading. Bionano did not disclose a targeted number of shares nor price in its offering, but the stock still fell more than 8% in the extended session.
- 01/19/2021
|
Bionano Genomics Announces Proposed Underwritten Public Offering of Common Stock
- SAN DIEGO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), announced today that it plans to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. Bionano also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock offered in the offering, to cover over-allotments, if any. All of the shares in the proposed offering are to be sold by Bionano.
- 01/19/2021
|
Map a Course for Breakthrough Science With BioNano Genomics
- BNGO stock is on the move as an up-and-coming biotech firm leverages the power of optical genome mapping technology. The post Map a Course for Breakthrough Science With BioNano Genomics appeared first on InvestorPlace.
- 01/19/2021
|
Day Five of Bionano's Next-Generation Cytogenomics Symposium: Saphyr Identifies Structural Variants that May Predispose to Severe COVID-19 Illness
- SAN DIEGO, Jan. 18, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced that the last day of its five-day Next-Generation Cytogenomics Symposium featured presentations by members of the COVID-19 Host Genome Structural Variant (SV) Consortium using the Saphyr® system for optical genome mapping (OGM) to analyze the genomes of patients with severe COVID-19 disease. The presentations by scientists and clinicians from leading hospitals and research institutions in Europe and the US showed that Saphyr was able to detect structural variants that may predispose to severe or mild COVID-19 disease, which had not been identified previously by large studies using next-generation sequencing (NGS) or array-based methods to analyze genomic variation.
- 01/18/2021
|
BNGO Stock Price Increases 1,552.94% Over The Past Month: Why It Happened
- The stock price of BioNano Genomics Inc (NASDAQ: BNGO) increased by 1,552.94% over the past month. This is why it happened.
- 01/16/2021
|
These Nasdaq Biotech Stocks Doubled in 2020. Here's Why They're Soaring on Friday
- Success tends to bring more success.
- 01/15/2021
|
Here's Why Bionano Genomics Stock Jumped Today
- Positive reviews from doctors have investors excited about the genome testing company's growth prospects.
- 01/15/2021
|
Day Four of Bionano's Next-Generation Cytogenomics Symposium: Saphyr Solves Genetic Mysteries, Enables Study of Complex Genetic Diseases, Simplifies Muscular Dystrophy Testing
- SAN DIEGO, Jan. 15, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced that day four of its five-day Next-Generation Cytogenomics Symposium featured seven Saphyr users presenting their results and experiences using the Saphyr® system for optical genome mapping (OGM) to analyze the genomes of patients with genetic diseases largely caused by the expansion or contraction of genomic repeats. Repetitive parts of the genome can expand to tens of thousands of copies and alter the function of genes they are in or near. Long repeats are typically inaccessible by sequencing, while OGM's imaging of long molecules allows for the repeats to be spanned and accurately sized. The presentations by scientists and clinicians from leading hospitals and medical research institutions in Europe and the US showed that Saphyr allows for the study of the many regions of the genome that contain repeats and couldn't be accurately assessed with sequencing technologies or other modern methods.
- 01/15/2021
|
Why Bionano Genomics Stock Surged Today
- The genome analysis specialist could help bring about better healthcare outcomes for people with cancer.
- 01/14/2021
|
Day Three of Bionano's Next-Generation Cytogenomics Symposium: Saphyr Provides Complete Structural Variation Analysis in Solid Tumors, Enables Discovery of Novel Diagnostic Markers and Drug Targets
- SAN DIEGO, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced that day three of its five-day Next-Generation Cytogenomics Symposium featured six Saphyr users presenting their results and experiences using the Saphyr® system for optical genome mapping (OGM) to analyze solid tumor genomes. The presentations by scientists and clinicians from leading hospitals and medical research institutions in Europe and the US discussed results on a variety of solid tumors such as cancers of the head and neck, brain, breast, liver, and the eye. All six studies showed that Saphyr enables for the first time a complete and clear picture of structural variation in the genome and provides opportunity for the discovery of novel cancer drivers, therapeutic targets, and prognostic markers, something which has not been possible to date with next-generation sequencing (NGS) and array platforms.
- 01/14/2021
|
Bionano Genomics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement
- SAN DIEGO, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), announced today that it has received a letter from the Nasdaq Listing Qualifications staff notifying the Company that it has regained compliance with Nasdaq's minimum bid price requirement for continued listing on the Nasdaq Capital Market. The letter noted that as for the last 10 consecutive business days, from December 29, 2020 to January 12, 2021, the closing bid price of the Company's common stock has been at $1.00 per share or greater, the Company has regained compliance with Listing Rule 5550(a)(2) and the matter is now closed.
- 01/13/2021
|
Day Two of Bionano's Next-Generation Cytogenomics Symposium: Saphyr Outperforms Standard Cytogenetics in Heme Malignancies, is Less Expensive, Provides Actionable Information Faster, in Single Assay
- SAN DIEGO, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced that day two of its five-day Next-Generation Cytogenomics Symposium featured eight Saphyr users presenting their results and experiences using the Saphyr® system for optical genome mapping (OGM) to analyze the genomes of patients with heme malignancies. The presentations by scientists and clinicians from leading hospitals and medical research institutions in Europe, the US and China discussed results on a variety of blood cancers, including Myelodysplastic Syndromes and a number of acute and chronic leukemias, and all 8 studies showed that Saphyr-based analyses of hematological malignancies can identify actionable variants detected by several cytogenomic methods combined, find additional important variants missed by traditional methods with prognostic and therapeutic value, and can do so with a shorter turn-around time and at a lower cost.
- 01/13/2021
|
Bionano Genomics Announces Closing of $101.8 Million Underwritten Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
- SAN DIEGO, Jan. 12, 2021 (GLOBE NEWSWIRE) -- BIONANO GENOMICS, INC. (Nasdaq: BNGO), announced today the closing of its previously announced underwritten public offering of 33,368,851 shares of its common stock, including 4,352,458 shares sold pursuant to the underwriters' exercise in full of their option to purchase additional shares, at a price to the public of $3.05 per share. The gross proceeds to Bionano from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $101.8 million.
- 01/12/2021
|
Why Bionano Genomics Stock Soared Today
- The genetic testing specialist is revealing new insights that could help explain why the coronavirus affects people differently.
- 01/11/2021
|
BNGO Stock Price Increased Over 20%: Why It Happened
- The stock price of Bionano Genomics Inc. (NASDAQ: BNGO) was trading at over 20% the stock price went from a previous close of $4.70 to a day high of $6.08. This is why it happened.
- 01/11/2021
|
COVID-19 Host Genome SV Consortium Identifies Structural Variants with Possible Roles in Pathogenesis and Outcomes in Severely Ill COVID-19 Patients Using Bionano's Saphyr® System
- First publication from international consortium highlights prowess of Saphyr in identifying large SVs with clinical significance and in COVID-19, an area with great public health implications First publication from international consortium highlights prowess of Saphyr in identifying large SVs with clinical significance and in COVID-19, an area with great public health implications
- 01/11/2021
|
Bionano Genomics Announces the Kick-Off of its Next-Generation Cytogenomics Symposium, The Largest Event Yet to Showcase Saphyr's Utility in Genome Analysis for Genetic Disease and Cancer
- SAN DIEGO, Jan. 10, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced the kick-off its 5-day Next-Generation Cytogenomics Symposium, which starts Monday January 11 and will feature 33 presentations by distinguished Saphyr users from leading hospitals and medical research institutions around the world. The presentations will cover applications of optical genome mapping (OGM) with Saphyr to analyze the genomes of patients with a variety of genetic diseases, blood cancers, solid tumors and repeat disorders as well as the studies supporting validation of clinical assays developed by Saphyr users. The last day of the symposium is dedicated to the study of the genomes of severely ill COVID-19 patients. The event is being held virtually and concludes on January 15, 2021.
- 01/10/2021
|
Why Bionano Genomics Stock Plunged Today
- The genetic testing specialist is selling shares at a discount.
- 01/08/2021
|
Bionano Genomics prices offering of 29 million shares at discount of $3.05 a share
- Bionano Genomics Inc. said Friday it has priced an underwritten public offering of 29 million shares at $3.05 a share. The stock closed Thursday at $5.00.
- 01/08/2021
|
Bionano Genomics Announces Pricing of $88.5 Million Underwritten Public Offering of Common Stock
- SAN DIEGO, Jan. 08, 2021 (GLOBE NEWSWIRE) -- BIONANO GENOMICS, INC. (Nasdaq: BNGO), announced today the pricing of its previously announced underwritten public offering of 29,016,393 shares of its common stock at a price to the public of $3.05 per share. The gross proceeds to Bionano from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $88.5 million. In addition, Bionano has granted the underwriters a 30-day option to purchase up to an additional 4,352,458 shares of common stock at the public offering price, less underwriting discounts and commissions, to cover over-allotments, if any. All of the shares in the proposed offering are to be sold by Bionano. The offering is expected to close on January 12, 2021, subject to customary closing conditions.
- 01/08/2021
|
Bionano Genomics shares fall after plan to sell more stock
- Bionano Genomics Inc. plans to sell more shares after a sudden surge in its stock price in recent weeks, and shares dove in after-hours trading Thursday in response. The company revealed Thursday afternoon that it expects to sell more shares under a shelf prospectus filed in August, but did not spell out how many shares it plans to sell nor at what price.
- 01/07/2021
|
Bionano Genomics Announces Proposed Underwritten Public Offering of Common Stock
- SAN DIEGO, Jan. 07, 2021 (GLOBE NEWSWIRE) -- BIONANO GENOMICS, INC. (Nasdaq: BNGO), announced today that it plans to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. Bionano also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock offered in the offering, to cover over-allotments, if any. All of the shares in the proposed offering are to be sold by Bionano.
- 01/07/2021
|
Small Cap Momentum Stocks on the Radar (NASDAQ: BNGO) (OTC US: MMEDF) (OTC US: LVGI) (OTC US: HVBTF)
- Bull markets mature into frenzied displays of greed, hope, and naked euphoria before they die. But that last stage can go on sometimes for years, as we saw in the latter half of the 1990's.
- 01/06/2021
|
BNGO Stock Price Increased 156.48% This Past Week: Why It Happened
- The stock price of BioNano Genomics Inc (NASDAQ: BNGO) has increased by 156.48% this past week. This is why it happened.
- 01/05/2021
|
Why Bionano Genomics Stock Skyrocketed More Than 100% Today
- The genetic testing specialist's tools could help to improve care for people with autism.
- 01/04/2021
|
Why Calithera, BioNano Genomics And More Are Moving Today
- Calithera Biosciences (NASDAQ: CALA) shares are trading lower after the company announced that its CANTATA study of Telaglenastat in Renal Cell Carcinoma did not achieve its primary endpoint. The company also announced a reduction in workforce by roughly 35%.
- 01/04/2021
|
BNGO Stock Alert: Why Bionano Genomics Stock Is Rocketing Again
- Bionano Genomics (BNGO) stock is taking off on Monday after announcing results from a recent genome study of Autism Spectrum Disorder. The post BNGO Stock Alert: Why Bionano Genomics Stock Is Rocketing Again appeared first on InvestorPlace.
- 01/04/2021
|
Bionano Genomics Shares Rally On Nasdaq Extension
- Shares of BioNano Genomics Inc (NASDAQ: BNGO) have doubled in price through the last two trading days. Before the rally, Bionano Genetics was struggling to maintain the $1-per-share price that is required to be listed on the Nasdaq.
- 12/31/2020
|
Bionano Genomics Granted 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule
- SAN DIEGO, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), announced today that Nasdaq has granted the Company an additional 180-day compliance period, or until June 28, 2021, to regain compliance with Nasdaq's minimum $1.00 closing bid price per share requirement.
- 12/30/2020
|
BNGO Stock Price Increased 50.42%: Why It Happened
- The stock price of BioNano Genomics Inc (NASDAQ: BNGO) increased by 50.42% as it went from a previous close of $0.88 to $1.33. This is why it happened.
- 12/30/2020
|
Bionano Customer Praxis Genomics Accredited by College of American Pathologists, Completing First LDT in US for Constitutional Genetic Disorders that Uses Whole Genome Analysis with Saphyr as Alternative to Chromosomal Microarray and Karyotyping
- SAN DIEGO, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), announced today that Praxis Genomics, LLC received accreditation from the College of American Pathologists (CAP), making it the first CAP-accredited, CLIA-certified diagnostic lab in the United States to offer a laboratory developed test (LDT) based on whole genome analysis with Saphyr. The LDT is designed for postnatal patients suspected of a constitutional genetic disorder. Praxis uses optical genome mapping (OGM) with Bionano's Saphyr System as an alternative to traditional methods of chromosomal microarray (CMA) and karyotyping (KT), as they seek to improve the rate of clinical diagnosis for patients with genetic disease. CMA and KT together typically diagnose 30-50% of patients tested. Recent studies have found that OGM with Saphyr is concordant with CMA and KT and also diagnoses a significant fraction (18-25%) of the patients who could not be diagnosed with traditional methods.
- 12/28/2020
|
Publication Reveals in Side-by-Side Comparison that Method Using PacBio Sequencing Detects Only 72% of the Large Structural Variants Detected by Optical Genome Mapping with Saphyr
- SAN DIEGO, Dec. 23, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced the publication of a study by the Human Genome Structural Variation Consortium (HGSVC) revealing that their sequencing method based on PacBio HiFi reads detected only 72% of the large SVs that Bionano's optical genome mapping (OGM) detected across 32 different human genomes. The consortium developed its custom sequencing method by combining sequencing with PacBio and the single-strand prep and sequencing method StrandSeq to establish a comprehensive catalog of human SVs with base-pair and haplotype resolution. The cost of this method is estimated, based on list pricing, to be between $10,000 and $20,000 per genome. OGM with Saphyr, which costs less than $500 per genome, was shown to be significantly more sensitive than the sequencing method.
- 12/23/2020
|
Bionano Genomics and its Users Present the Saphyr System for Optical Genome Mapping and Various Advancements in Clinical Variant Detection at AMP 2020
- SAN DIEGO, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced that the performance and application of its Saphyr system for optical genome mapping are being showcased at the Annual Meeting of the Association for Molecular Pathology (AMP), being held virtually at amp20.amp.org from November 16-20. AMP is widely recognized as the preeminent scientific society dedicated to advancing the clinical practice, science and excellence of molecular and genomic laboratory medicine. With over 2,500 members in over 50 countries working in the field of molecular pathology, its annual meeting is considered the prime event for presenting advances and technological innovations in molecular diagnostics to pathologists, laboratory directors and clinical professionals.
- 11/19/2020
|
Bionano Genomics Reports Third Quarter 2020 Financial Results and Provides Business Update
- Company to host conference call today, November 12, at 4:30 pm ET Company to host conference call today, November 12, at 4:30 pm ET
- 11/12/2020
|
Multi-Center Evaluation of Bionano Optical Genome Mapping by Cytogenetics Thought Leaders in the US Leads to Recommendation for Bionano's Saphyr to Replace Karyotyping as First-Line Test for Detection and Identification of Structural and Copy Number Variants in Leukemia Patients
- SAN DIEGO, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced the publication of a study led by cytogenetics experts from the nation's top clinical and cancer centers in which they recommended that optical genome mapping (OGM) using Bionano's Saphyr System be considered as a first-line test for detection and identification of clinically relevant structural variants and copy number variants in leukemias. The paper, published this week in medRxiv, describes detection and identification of structural variants and copy number variants in 100 patients with acute myeloid leukemia (AML). This study is the largest to-date in leukemia for Bionano and the first published study from the United States comparing Bionano's OGM to karyotyping, the current standard of care in leukemia testing.
- 11/11/2020
|
Largest Study To-Date Focused on Undiagnosed Genetic Disease Patients Reveals That Bionano's Optical Genome Mapping Technology Can Diagnose Significantly More Patients Than Standard of Care Methods Alone
- Publication from UCSF shows Bionano's optical genome mapping technology can detect pathogenic variants missed by whole exome sequencing and by chromosomal microarray in patients with rare genetic disorders and may contribute to more patients receiving definitive molecular diagnoses Publication from UCSF shows Bionano's optical genome mapping technology can detect pathogenic variants missed by whole exome sequencing and by chromosomal microarray in patients with rare genetic disorders and may contribute to more patients receiving definitive molecular diagnoses
- 11/05/2020
|
Prowess of Bionano Genomics' Saphyr System in Uncovering Novel Genetic Variations That Cause Cancer and Genetic Disease in Full Display at ASHG 2020
- Top researchers present discoveries in cancer predisposition, neurodegenerative diseases, microdeletion syndromes and other genetic disorders made using Bionano's optical genome mapping technology Top researchers present discoveries in cancer predisposition, neurodegenerative diseases, microdeletion syndromes and other genetic disorders made using Bionano's optical genome mapping technology
- 10/27/2020
|
Bionano Genomics: Intriguing Technology. Troubling Trajectory
- Today, we look at a very small concern with potentially game changing technology in a fast-growing part of the healthcare market.
- 09/08/2020
|
Bionano Genomics Appoints Industry Leading Cytogeneticist Dr. Alka Chaubey as the Company’s First Chief Medical Officer to Help Lead the Conversion of Cytogenetics to Digital Cytogenetics with Saphyr
- Dr. Chaubey is a key opinion leader in cytogenetics who has developed, validated and commercialized dozens of molecular and cytogenetic tests based on next generation sequencing, microarray and COVID-19 RT-PCR, she has led the FDA clearance of diagnostic tests and led the efforts to obtain reimbursement for novel assays that are widely used. Her experience will guide Bionano towards its goal of widespread clinical adoption of Saphyr.SAN DIEGO, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that Dr. Alka Chaubey, PhD, FACMG, will join Bionano as its first Chief Medical Officer, effective August 31, 2020. Dr. Chaubey is well known throughout the molecular diagnostics and cytogenetics communities for her contributions to innovation directed toward improving patient outcomes by making the clinical testing process more efficient and more effective. Her breadth of experience includes developing and validating clinical tests, leading the process to obtain FDA clearance for whole-genome cytogenetic tests, engaging with third party payors to obtain reimbursement for novel assays, running clinical trials and leading CLIA-certified, CAP-accredited laboratories as their laboratory director. As Chief Medical Officer of Bionano, she will take the lead in driving toward our goal of global, widespread adoption of Saphyr for use in various clinical applications, including digital cytogenetics. Dr. Chaubey comes to Bionano with almost 20 years of scientific and clinical experience, including at PerkinElmer, where she currently serves as the Head of Cytogenomics for PerkinElmer Genomics and for Vanadis. She holds an academic appointment as the Scientific Director of the Georgia Esoteric and Molecular Laboratory, Scientific Director of the Cytogenetics Laboratory of the Augusta University Medical Center and Adjunct Assistant Professor of Pathology of the Medical College of Georgia at Augusta University. Previously, Dr. Chaubey was Director of the Cytogenomics Laboratory of the Greenwood Genetic Center. Her breadth of clinical experience spans an array of clinical indications, including constitutional disorders, non-invasive prenatal Testing (NIPT) assay for common aneuploidies, the FDA Laboratory Developed Test (LDT-EUA) submissions for COVID-19 assays, a Bionano Saphyr-based test for Facioscapulohumeral Muscular Dystrophy (FSHD1) and other sequencing based tests, including whole genome sequencing. She was also central in the FDA clearance for the first IVD whole genome microarray, CytoScan DX from Affymetrix, now part of Thermo Fisher Scientific. Dr. Chaubey is widely respected as a thought leader and innovator in the cytogenetic and molecular diagnostic community, serving on multiple advisory boards and consortia management boards.Erik Holmlin, PhD, CEO of Bionano Genomics commented: “I am so happy that Dr. Alka Chaubey is joining Bionano as the first Chief Medical Officer in the history of our company. Alka complements our leadership team by bringing clinical and scientific expertise that can take Bionano’s capabilities to the next level and accelerate commercial execution for Bionano and its customers. Over the years that Alka has advised Bionano, we have built a strong relationship of mutual trust and respect. We cannot think of a better fit for us than Alka and believe her experience will help turn Bionano’s current string of initial successes in translational and clinical research into a movement in molecular diagnostics that we believe could revolutionize cytogenetic testing in cancer and genetic disease.”About Bionano GenomicsBionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing. Bionano’s Saphyr system is a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. The Saphyr system is comprised of an instrument, chip consumables, reagents and a suite of data analysis tools, and genome analysis services to provide access to data generated by the Saphyr system for researchers who prefer not to adopt the Saphyr system in their labs. For more information, visit www.bionanogenomics.com.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: Saphyr’s ability to comprehensively detect all classes of chromosomal aberrations; Saphyr’s use as a viable alternative to traditional cytogenetic methods; the contribution of Dr. Chaubey’s experience and past achievements in helping us achieve our strategic objectives; Dr. Chaubey’s expected role on our executive team and in driving widespread clinical adoption of the Saphyr system; the advancement of our strategic plans; and Saphyr’s capabilities, including its ability to resolve the most complex regions of the genome. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive products; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the loss of key members of management and our commercial team; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2019 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.CONTACTS Company Contact: Erik Holmlin, CEO Bionano Genomics, Inc. +1 (858) 888-7610 eholmlin@bionanogenomics.comInvestor Relations Contact: Ashley R. Robinson LifeSci Advisors, LLC +1 (617) 430-7577 arr@lifesciadvisors.comMedia Contact: Darren Opland, PhD +1 (617) 733-7668 darren@lifescicomms.com
- 08/18/2020
|
Stick With BioNano Genomics (BNGO) Stock as Consumable Revenue Growth Accelerates, Says Analyst
- 2020 is turning out to be a roller-coaster ride for investors of life science company BioNano Genomics (BNGO). Over the past six trading sessions, the share price has declined by 23%. The drop, however, was preceded by a massive 130% gain between early May and August. Yet, one 5-star analyst expects the extreme market gyrations to continue with a further swing upwards over the next 12 months. Oppenheimer analyst Kevin DeGeeter rates BNGO shares a Buy along with a $1.50 price target, which implies nearly 130% upside from current levels. (To watch DeGeeter’s track record, click here)DeGeeter’s confidence is based on BioNano’s role in cytogenetics – the study of chromosomal structures. Specifically, the potential of the company's genome imaging system, Saphyr.“Our thesis on BNGO has been based on the potential of Saphyr to increase consumable revenues through validation and adoption for use in cytogenetics testing. Management noted labs validating Saphyr for cytogenetics accounted for roughly half of consumable revenues, which by our estimates accounted for most of the growth for this segment. Mgmt expects results from the first large validation cohort of US cytogenetics patients to be published in coming weeks.”The numbers back up DeGeeter’s claims. In its latest “better-than-expected” 2Q20 earnings report, consumable revenues grew year-over-year by 79% to $711,000, with a strong showing in Europe in particular.In fact, DeGeeter believes that in Europe, cytogenetics is “building toward a tipping point.” Validation studies for cytogenetics are being completed in labs in Germany, Italy, the Netherlands. But the European adoption only offers “upside” to DeGeeter’s Saphyr outlook. Yet, the bulk of the analyst’s forecast is based on US cytogenetics adoption.“We expect growth in cytogenetics consumable revenue in the US to accelerate in 4Q20 following potential publication in medical journal of important validation findings from cytogenetics analysis from various hematologic malignancies,” the top analyst said.Overall, DeGeeter has two additional analysts backing up his positive thesis. The two extra Buys result in a Strong Buy consensus rating and a $1.47 average price target. The potential upside, according to these analysts, is a tidy 124%. (See BioNano stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
- 08/17/2020
|
Would Shareholders Who Purchased Bionano Genomics'(NASDAQ:BNGO) Stock Year Be Happy With The Share price Today?
- It is a pleasure to report that the Bionano Genomics, Inc. (NASDAQ:BNGO) is up 81% in the last quarter. But that...
- 08/17/2020
|
Bionano Genomics Announces “At-The-Market” Equity Program
- SAN DIEGO, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that it has filed a prospectus with the Securities and Exchange Commission (“SEC”), under which it may offer and sell shares of its common stock (the “Shares”) having an aggregate offering price of up to $40,000,000 from time to time through an “at-the-market” equity offering program (the “ATM Program”). Bionano currently intends to use the net proceeds from sales of Shares under the ATM Program, if any, for working capital and general corporate purposes, including research and development expenses, discharge of indebtedness and capital expenditures. The timing of any sales will depend on a variety of factors to be determined by Bionano. The Shares will be offered through Ladenburg Thalmann & Co. Inc. (“Ladenburg”) as sales agent. Sales of Shares may be made by any method permitted by law deemed to be an “at-the-market offering” as defined in Rule 415 of the Securities Act of 1933, as amended. Bionano is not obligated to sell any Shares under the ATM Program. Each time Bionano wishes to issue and sell Shares under the ATM Program, Bionano will notify Ladenburg of the number of Shares to be issued, the dates on which such sales may be made, any limitation on the number of Shares to be sold in any one day and any minimum price below which sales may not be made. Unless Ladenburg declines to accept the terms of such notice, Ladenburg has agreed to use its commercially reasonable efforts consistent with its normal trading and sales practices to sell such Shares up to the amount specified on such terms.The prospectus relating to the ATM Program, filed on August 14, 2020 (the “ATM Prospectus”), adds to, updates or otherwise changes information contained in the accompanying base prospectus contained in a shelf registration statement on Form S-3 (File No. 333-245762) (the “Registration Statement”) for the offering of Shares. Prospective investors should read the base prospectus, the ATM Prospectus and other documents Bionano has filed with the SEC (some of which are incorporated by reference into the base prospectus and the ATM Prospectus) for more complete information about Bionano, the ATM Program and the risks Bionano currently is facing due to the spread of COVID-19. You may obtain copies of the base prospectus and the ATM Prospectus without charge by visiting the SEC’s website at www.sec.gov.The Registration Statement has been filed with the SEC but has not yet become effective. The Shares may not be sold nor may offers to buy be accepted prior to the time the Registration Statement becomes effective.This press release is for informational purposes only and is not an offer to sell or the solicitation of an offer to buy any Shares of Bionano, which is made only by means of the ATM Prospectus and related base prospectus. There will be no sale of Shares in any jurisdiction in which the offer, solicitation of an offer to buy or sale would be unlawful.About Bionano Genomics Bionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing. Bionano’s Saphyr system is a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. The Saphyr system is comprised of an instrument, chip consumables, reagents and a suite of data analysis tools, and genome analysis services to provide access to data generated by the Saphyr system for researchers who prefer not to adopt the Saphyr system in their labs.Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the ATM Program, the expected proceeds and uses thereof, and Saphyr’s capabilities, including its ability to resolve the most complex regions of the genome. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive products; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the loss of key members of management and our commercial team; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2019 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.CONTACTS Company Contact: Erik Holmlin, CEO Bionano Genomics, Inc. +1 (858) 888-7610 eholmlin@bionanogenomics.comInvestor Relations Contact: Ashley R. Robinson LifeSci Advisors, LLC +1 (617) 430-7577 arr@lifesciadvisors.com
- 08/17/2020
|
Bionano Genomics, Inc. (BNGO) CEO Erik Holmlin on Q2 2020 Results - Earnings Call Transcript
- Bionano Genomics, Inc. (NASDAQ:BNGO) Q2 2020 Earnings Conference Call August 13, 2020 4:30 PM ET Company Participants Ashley Robinson - LifeSci Advisors Erik Holmlin - Chief Executive Officer Conference Call Participants Kevin DeGeeter - Oppenheimer Adheip Mally - Maxim Group Presentation Operator Greetings.
- 08/13/2020
|
Bionano Genomics Reports Second Quarter 2020 Financial Results and Provides Business Update
- Company to host conference call today, Thursday, August 13, at 4:30 pm ETSAN DIEGO, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr®, a platform for ultra-sensitive and ultra-specific structural variation detection in genome analysis, today reported its financial results for the second quarter ended June 30, 2020 and provided a business update. Recent Business Highlights * From January 1, 2020 through today, processed 493 customer samples, compared to a total of 212 customer samples processed during all of 2019. * Since commercial launch in February 2017 through today, 91 Saphyr instruments have been installed. * Announced the publication of data demonstrating 100% concordance between Saphyr system and current gold standard cytogenetic methods in several publications and posters, including: * in an online presentation hosted by the Cancer Genomics Consortium (CGC) on May 12, 2020, Dr. Brynn Levy from Columbia University and Dr. Rashmi Kanagal-Shamanna from the MD Anderson Cancer Center each presented data showing 100% concordance between Bionano Genomics’ optical mapping technology and current gold standard cytogenetic methods in leukemia; * in multiple presentations at the European Society of Human Genetics (ESHG) Conference, data showed the Saphyr system had detected/solved previously unidentified genetic mutations and demonstrated 100% concordance with standard cytogenetics in leukemias and constitutional aberrations, with Dr. Alexander Hoischen from Radboud University Medical Center concluding that the Saphyr system may allow “a Cytogenetics Revolution”; and * announced first publication in a large study from a European consortium, in which (i) the authors reported 100% concordance between optical mapping results from the Saphyr system and gold standard cytogenetic methods in a cohort of patients with a variety of constitutional or inherited genetic disorders, (ii) for leukemia patients, Saphyr enabled key discoveries including novel fusion events never described before in that disease. Saphyr solved previously unidentified genetic diseases by finding novel mutations. * Significantly expanded scope of research with the COVID-19 host genome structural variant consortium, formed by Dr. Ravindra Kolhe at Augusta University, which is using Bionano genome imaging to research COVID-19 susceptibility. Saphyr’s extremely sensitive structural variation detection technology is expected to be used to analyze samples from COVID-19 patients from dozens of clinical sites throughout North America and Europe. The consortium includes more than 40 world-renowned scientists and institutions. * Strengthened IP with the receipt of US Patent No. 10,676,352 entitled “Nanonozzle Device Arrays: Their Preparation and Use for Macromolecular Analysis,” covering the addition of a detector, such as a nanopore, to Bionano’s patented nanochannels. The patent describes how such nanodetector could detect DNA sequence information, detect the presence or absence of chemical modifications or specific labels attached to the DNA using a variety of detection technologies, and how such nanochannel-nanodetector combination array, called a nanonozzle device array, can be manufactured. * Continued growth of installed base of the Saphyr system across the globe, with adoption for digital cytogenetic applications by the UK NHS, the Medical College of Wisconsin, University of Iowa and the Leading South Korean Yonsei University Hospital among the newest adopters. * Launched a new Bionano Prep™ SP Tissue and Tumor Kit enabling routine analysis of cancer biopsies and animal tissue expanding its addressable market to include solid tumors and model genomes commonly studied in pharmaceutical research and development. * Added to growing list of publications, including: * the European consortium publication discussed above, which demonstrated that Saphyr detected all 100 chromosomal aberrations in 85 samples from genetic disease patients, underscoring Bionano’s continued progress towards its goal of Saphyr becoming the new standard of digital cytogenetic testing; * a publication in Nature, for which Saphyr data was considered the gold standard for structural accuracy used to correct structural errors in the first complete telomere-to-telomere assembly a human X-Chromosome; * in another publication in Nature, which documented the largest study of a single genetic disorder using Bionano genome imaging technology to date, in which Bionano genome imaging identified the most common structural variations between individuals with DiGeorge Syndrome and was shown to be the only system capable of resolving this extremely complex genome structure; and * in another publication in Nature, in which Bionano genome imaging provided essential scaffolding results for six reference-quality bat genomes to help reveal how bats can carry and yet survive deadly viruses. * Appointed Hannah Mamuszka and Yvonne Linney, Ph.D., to the Board of Directors, adding proven business leadership with strategic knowledge of commercialization of diagnostics in support of Bionano’s mission of developing solutions in digital cytogenetics and genomics research * In April 2020, completed an underwritten public offering of common stock, pre-funded warrants to purchase shares of common stock, and accompanying common warrants, resulting in approximately $18 million in gross proceeds to the Company, before deducting underwriting discounts and commissions and other offering expenses payable by the Company.“We have made great strides towards validating the scientific credibility of our Saphyr System as we work to establish it as the new gold standard in cytogenetic methods. To that end, we saw leading researchers publish data showing 100% concordance with current cytogenetic methods,” said Erik Holmlin, Ph.D., CEO of Bionano. “Also, we are enabling researchers to develop an understanding of SARS-CoV-2, the virus that causes COVID-19, through our partnership with the structural variant consortium, formed by Dr. Ravindra Kolhe at Augusta University. The scope of work with the consortium was significantly expanded and now includes work analyzing samples from COVID-19 patients around the globe.”Second Quarter Financial ResultsTotal Revenue. Total revenue decreased by $1.0 million, or 45.7%, to $1.2 million for the three months ended June 30, 2020 compared to $2.2 million for the same period in 2019. The decrease impacted all geographic regions, largely driven by customers temporarily shutting down their lab operations in response to the COVID-19 pandemic. Below is a summary of changes for the three months ended June 30, 2020 as compared to the same period in 2019: * North America revenue decreased by $0.6 million, or 43%; * EMEIA revenue decreased by $0.2 million, or 38%; and * Asia Pacific revenue decreased by $0.2 million, or 73%.Cost of Revenue. Total cost of revenue decreased by $1.0 million, or 61.2%, to $0.6 million for the three months ended June 30, 2020 compared to $1.6 million for the same period in 2019, primarily due to a decrease in the number of instrument units sold during the quarter from 8 to 1. This was partially offset by an increase in consumable units sold of 189%.Operating Expenses. Operating expenses increased by approximately $0.5 million, or 7.4%, to $8.0 million for the three months ended June 30, 2020, compared to $7.5 million for the same period in 2019. The increase was primarily due to headcount additions to our global sales and marketing teams as well as back-office support teams to assist with the growth of our world-wide product distribution. In addition, we incurred increased professional fees to support ongoing business operations and our international presence. Salary reductions implemented in April 2020 partially offset cost increases driven by our headcount additions.Cash and cash equivalents. At June 30, 2020, the Company had cash and cash equivalents of $17.2 million compared to cash and cash equivalents of $17.3 million at December 31, 2019.First Half 2020 Financial ResultsTotal Revenue. Total revenue decreased by $1.7 million, or 42.4%, to $2.3 million for the six months ended June 30, 2020 compared to $4.0 million for the same period in 2019. The decrease impacted all regions, largely driven by customers temporarily shutting down their lab operations in response to the COVID-19 pandemic. Below is a summary of changes for the six months ended June 30, 2020 as compared to the same period in 2019: * North America revenue decreased by $0.7 million, or 32%; * EMEIA revenue decreased by $0.7 million, or 51%; and * Asia Pacific revenue decreased by $0.3 million, or 74%.Cost of Revenue. Total cost of revenue decreased for the six months ended June 30, 2020 as compared to 2019 primarily due to a decrease in the number of instruments units sold from 14 to 4. This was partially offset by an increase in consumable units sold of 120%.Operating Expenses. Operating expenses increased by approximately $3.7 million, or 25.8%, to $18.1 million for the six months ended June 30, 2020, compared to $14.4 million for the same period in 2019. Research and development expenses increased $0.6 million, or 12.6%, to $5.1 million for the six months ended June 30, 2020 compared to $4.5 million for the same period in 2019. This is due to headcount additions to our development teams, but slightly offset by the salary reductions implemented in April 2020. In addition, our materials and supply expense increased during the six months ended June 30, 2020 due to continued efforts to innovate our product. Selling, general and administrative expenses increased by $3.1 million, or 31.8%, to $13.
- 08/13/2020
|
Bionano Featured at Cancer Genomics Consortium Annual Meeting with Multiple Data Readouts that Further Validate Saphyr in the Field of Cytogenetics and Lay Groundwork for a Novel LDT in Cancer
- * In a new study at Children’s Hospital of Los Angeles evaluating children with B-ALL, the most common type of cancer in children, researchers using Saphyr discovered an oncogenic variation that they believe may cause the disease in some patients and could be prognostic of disease severity and relapse * Findings from a new study at Augusta University analyzing 20 leukemias and solid tumors showed that Saphyr detected 100% of the previously identified genomic variants, revealed many novel variants previously not known and identified precise breakpoints and partners of several translocationsSAN DIEGO, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that the 2020 Cancer Genomics Consortium Annual Meeting held on August 4 and 5 featured several studies using Bionano genome imaging. Results of these studies underscore that Saphyr has the potential to modernize cytogenetics by consolidating analysis performed with each of the three standard cytogenetic methods (karyotyping, FISH and chromosomal microarray) into a single assay with performance that matches or exceeds that of these three methods combined.The Cancer Genomics Consortium (CGC) is an organization comprised of leading cytogeneticists, molecular geneticists and molecular pathologists. Its annual meeting attracts the key opinion leaders and cytogenetics directors from North America’s leading cancer centers and hospitals. In the last several years, the meeting has seen an increasing presence of studies and presentations featuring data generated using Bionano’s Saphyr genome imaging system. At this year’s virtual event, four speakers shared their results generated with Saphyr.Dr. Gordana Raca from the Children’s Hospital of Los Angeles (CHLA) presented the case of a 2-year old boy with B-cell acute lymphoblastic leukemia (B-ALL) who had been tested by the traditional methods of karyotyping, an extensive FISH panel and chromosomal microarray (CMA), as well as with an advanced custom sequencing panel for pediatric cancer, with no genetic driver of the disease found. CMA analysis called a duplication in the PAX5 gene, a known oncogene, but upon analysis with Saphyr, the two extra copies of the gene were shown to be four extra copies in tandem. In a second child with similar disease, Saphyr called five extra copies of the same oncogene, while CMA called only 2. The unambiguous resolution of these variants by Saphyr demonstrated the advantage of genome imaging of single molecules over hybridization-based methods like CMA. The extra copies of parts of the PAX5 gene are believed to be the primary driver of the disease in the patients, and to be correlated with a poor prognosis, including relapse and more severe progression of the disease.Dr. Nikhil Sahajpal from Augusta University presented results on 20 cancer patients, including leukemia patients with acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and myelodysplastic syndromes (MDS) who were previously characterized by karyotyping and FISH analysis, and patients with solid tumors, previously characterized by OncoScan microarray. In all samples, Saphyr detected all previously found variants. Additionally, Saphyr identified variants that were not called by karyotyping and FISH, contributing to resolution of complex rearrangements with previously unclear structure, and the identification of precise breakpoints of pathogenic variants and many previously unknown translocation partners. In the solid tumor samples, Saphyr identified all previously identified events and also identified multiple translocations that are impossible to detect by microarray. These results form the basis for creating a Laboratory Developed Test (LDT) for cancer by Dr. Ravindra Kolhe’s team at Augusta University. The project aims to validate Saphyr as a first-tier diagnostic tool for solid tumors and hematological malignancies and to lay the groundwork for reimbursement codes for labs based in the United States.In addition to those new results, Dr. Alex Hoischen from Radboud Univeristy presented the previous reported validation studies by his team and an international consortium on 48 leukemia samples and 85 patients with constitutional disease, both showing 100% concordance between Saphyr and standard cytogenetics. Dr Hoischen also presented certain novel research findings, including new genetic variants that could form the basis of more refined testing algorithms in the future.Talks at CGC covering other technologies including long-read sequencing and nanopore sequencing provided additional support for Bionano genome imaging with Saphyr as a leading technology for modernizing cytogenetics. For example, Evan Eichler from the University of Washington discussed in his keynote talk on various long-read genome analysis technologies that the largest structural variants (the ones with known clinical significance and utility) can be detected by Bionano genome imaging but not by long-read sequencing. Finally, in a presentation on nanopore sequencing, Dr. William Gleen from Medical University of South Carolina described the need to use 10 different bioinformatic algorithms to obtain a set of structural variation calls, yet this data included a high rate of wrong calls (false positives and false negatives). Erik Holmlin, PhD, CEO of Bionano Genomics commented: “The continuous progress of studies from members of the CGC demonstrating the ability of Saphyr to consolidate and replace all three standard cytogenetic methods is impressive. We believe that the newly reported results from CHLA and Augusta University add to the increasing evidence supporting that Saphyr is not only a replacement, but a significant improvement to cytogenetic analysis for both solid tumors and leukemias. The high engagement of the CGC community that we have seen at previous conferences continued at this year’s virtual event, with our virtual booth receiving continuous visits and participating in discussions. The LDT being developed by Augusta University adds to the large number of accreditation studies in Europe, which we believe opens the door for potential widespread adoption of Saphyr in cytogenetic labs around the world.”About Bionano GenomicsBionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing. Bionano’s Saphyr system is a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. The Saphyr system is comprised of an instrument, chip consumables, reagents and a suite of data analysis tools, and genome analysis services to provide access to data generated by the Saphyr system for researchers who prefer not to adopt the Saphyr system in their labs. For more information, visit www.bionanogenomics.com.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: Saphyr’s potential as a replacement of traditional cytogenetic testing methods and improvement in cytogenetic analysis; the contributions of ongoing studies towards the understanding and treatment of disease; timing and anticipated impact of the LDT in development at Augusta University; and widespread adoption of Saphyr in cytogenetic labs around the world. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: general market conditions; changes in the competitive landscape and the introduction of competitive products; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the loss of key members of management and our commercial team; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2019 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.CONTACTS Company Contact: Erik Holmlin, CEO Bionano Genomics, Inc. +1 (858) 888-7610 eholmlin@bionanogenomics.comInvestor Relations Contact: Ashley R. Robinson LifeSci Advisors, LLC +1 (617) 430-7577 arr@lifesciadvisors.comMedia Contact: Kirsten Thomas The Ruth Group +1 (508) 280-6592 kthomas@theruthgroup.com
- 08/10/2020
|
Bionano (BNGO) to Report Q2 Earnings: What's in the Offing?
- Bionano's (BNGO) sales numbers will be in focus when it reports Q2 results later in the week.
- 08/10/2020
|
Bionano Genomics to Report Second Quarter 2020 Financial Results and Host a Conference Call and Webcast on August 13
- SAN DIEGO, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr®, a platform for ultra-sensitive and ultra-specific structural variation detection in genome analysis, today announced that it will host a conference call and live webcast on Thursday, August 13, 2020 at 4:30 p.m. Eastern Time to report financial results for its second quarter ended June 30, 2020 and provide a business update. Among the highlights the company plans to cover is an update regarding the approximately $14 million in cash proceeds the company received pursuant to warrant exercises since the end of the second quarter. Accordingly, the company believes that its current cash and cash equivalents are sufficient to fund the company's operations into the first quarter of 2021. Conference Call & Webcast Details Date:Thursday August 13th Time:4:30 p.m. Eastern Time Toll Free:877-407-0784 International:201-689-8560 Conference ID:13706933 Webcast:http://public.viavid.com/index.php?id=140743 To access the call, participants should dial the applicable telephone number above at least 5 minutes prior to the start of the call. An archived version of the webcast will be available for replay in the Investors section of the Bionano website.About Bionano Genomics Bionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing. Bionano's Saphyr system is a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. The Saphyr system is comprised of an instrument, chip consumables, reagents and a suite of data analysis tools, and genome analysis services to provide access to data generated by the Saphyr system for researchers who prefer not to adopt the Saphyr system in their labs. For more information, visit www.bionanogenomics.com.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our expectations regarding the sufficiency of the company’s cash and cash equivalents to fund operations for a specified time period. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive products; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the loss of key members of management and our commercial team; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2019 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.Contacts Company Contact: Erik Holmlin, CEO Bionano Genomics, Inc. +1 (858) 888-7610 eholmlin@bionanogenomics.comInvestor Relations Contact: Ashley R. Robinson LifeSci Advisors, LLC +1 (617) 430-7577 arr@lifesciadvisors.comMedia Contact: Kirsten Thomas The Ruth Group +1 (508) 280-6592 kthomas@theruthgroup.com
- 08/07/2020
|
Studies on COVID-19 Disease Susceptibility in China Using Bionano Genomics’ Saphyr Are Progressing and Generating High Quality Data
- Samples collected from COVID-19 patients from initial outbreaks in China were analyzed successfullySAN DIEGO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that significant progress has been made in previously announced COVID-19 host genetics studies on the initial COVID-19 outbreaks in Wuhan and Shanghai, and that researchers have successfully analyzed patient samples using Bionano Saphyr at the site of Wuhan-based service provider GrandOmics. These studies aim to compare a variety of genomic and other biological variables between those patients who show no or mild symptoms and those who show severe illness, while controlling for viral strain differences, and for the known risk factors of age and chronic illness such as asthma, heart disease, diabetes, or other immune-compromising disease. Both the Wuhan and Shanghai studies had suffered from setbacks due to institutional and governmental restrictions on the analysis of genomic DNA of the COVID-19 patients for these host genome studies, and additional restrictions on transporting patient samples for processing delayed progress in these studies. These hurdles have now been cleared, and the first four samples from COVID-19 patients from the Shanghai cohort have been successfully processed, generating exceptional DNA and data quality metrics. Samples from the Wuhan cohort have been identified as well and are awaiting processing.Bionano Genomics expects that its Saphyr genome imaging technology can provide important structural variation data needed for a full understanding of genome structure in COVID-19 patients. As previously announced on July 24, 2020, initial unpublished findings from 30 COVID-19 patients that have been analyzed on Saphyr as part of the COVID-19 Host Genome Structural Variation Consortium show that Saphyr detects large amounts of structural variation in many putatively relevant genes, demonstrating that point mutations alone are unlikely to explain disease differences between patients.Erik Holmlin, PhD, CEO of Bionano Genomics commented: “We believe that the work in these studies can prove to be essential for the development of new therapies, vaccines and diagnostics designed to improve patient management for those patients with COVID-19. While studies in Europe and in North America centered around the COVID-19 Host Genome Structural Variation Consortium are ongoing, we are pleased that the host genome studies of the initial outbreak in China are now progressing as well. We are proud of our team and our collaborators who have overcome significant barriers to make this progress.”About Bionano Genomics Bionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing. Bionano’s Saphyr system is a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. The Saphyr system is comprised of an instrument, chip consumables, reagents and a suite of data analysis tools, and genome analysis services to provide access to data generated by the Saphyr system for researchers who prefer not to adopt the Saphyr system in their labs. For more information, visit www.bionanogenomics.com.Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: progress in studies involving our genome imaging technology; expectations regarding the utility of Saphyr genome imaging technology in COVID-19 research; and the outcomes of studies involving our genome imaging technology, including with respect to COVID-19 research and development of potential treatments for COVID-19 patients. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: delays in studies and other research activities involving our technology, including due to institutional, governmental and other restrictions; the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive products; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the loss of key members of management and our commercial team; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2019 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.CONTACTS Company Contact: Erik Holmlin, CEO Bionano Genomics, Inc. +1 (858) 888-7610 eholmlin@bionanogenomics.comInvestor Relations Contact: Ashley R. Robinson LifeSci Advisors, LLC +1 (617) 430-7577 arr@lifesciadvisors.comMedia Contact: Kirsten Thomas The Ruth Group +1 (508) 280-6592 kthomas@theruthgroup.com
- 08/06/2020
|
Bionano Genomics, Inc. (BNGO) Gains But Lags Market: What You Should Know
- Bionano Genomics, Inc. (BNGO) closed the most recent trading day at $0.79, moving +0.25% from the previous trading session.
- 08/03/2020
|
Metastatic Lung Cancer Study Finds That Bionano’s Saphyr Outperforms NGS for the Detection of Structural Variants
- SAN DIEGO, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced the publication of the first study to utilize its genome imaging system, Saphyr, for the analysis of structural variants (SVs) in lung cancer and metastases. The study, published in Translational Lung Cancer Research by a team of scientists from Fudan University Shanghai Cancer Center and Shanghai Medical College, analyzed SVs using both short-read next-generation sequencing technology (NGS) and Bionano’s Saphyr system on a primary lung squamous cell carcinoma sample, and on matched metastases from lymph node and pulmonary vein. The study showed that Saphyr outperformed NGS-based methods in the detection of structural variants to characterize the genetic heterogeneity between the primary tumor and the matched metastases. Of 1026 large SVs detected on average by Saphyr in each of the tumor types, the NGS-based methods failed to detect an average of 77%. Saphyr identified 52 SVs shared between the metastases, while no shared SVs were found by NGS-based methods.The study authors stated that Saphyr is more capable of detecting large and complex SVs, without the computational and bioinformatic challenges that come with SV calling from NGS data. They found that like with point mutations and small insertions/deletions detected with NGS, SVs make up a large part of tumor heterogeneity. The authors describe that the combination of NGS and Saphyr allowed for a more comprehensive understanding of the variation between primary tumor and metastases, with Saphyr making up for the inability of NGS to detect large SVs.Erik Holmlin, Ph.D., CEO of Bionano Genomics commented: “Researchers are increasingly becoming aware of the importance of genome-wide and unbiased detection of structural variants in cancer and of the severe limitations of NGS-based methods to do so. We are pleased to see this publication showing that Saphyr provided a comprehensive view of structural variants in lung cancer, the most commonly occurring cancer worldwide. Unlike short-read sequencing protocols which start with fragmenting the genomic DNA of the tumor, Bionano’s genome imaging analyzes long, intact DNA molecules that are hundreds of thousands to millions of basepairs long, which enables Saphyr to detect structural variants that couldn’t be identified before. We believe this study and the growing body of publications on Bionano data show that Saphyr is indispensable for personalized medicine and for furthering the understanding of tumorigenesis and cancer progression.”The study is available at http://tlcr.amegroups.com/article/view/40176/html.About Bionano GenomicsBionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing. Bionano’s Saphyr system is a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. The Saphyr system is comprised of an instrument, chip consumables, reagents and a suite of data analysis tools, and genome analysis services to provide access to data generated by the Saphyr system for researchers who prefer not to adopt the Saphyr system in their labs. For more information, visit www.bionanogenomics.com.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: Saphyr’s capabilities in comparison to NGS-based methods; and Saphyr’s potential as an indispensable tool for personalized medicine and furthering understanding of cancer in the medical community. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive products; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the loss of key members of management and our commercial team; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2019 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.CONTACTS Company Contact: Erik Holmlin, CEO Bionano Genomics, Inc. +1 (858) 888-7610 eholmlin@bionanogenomics.comInvestor Relations Contact: Ashley R. Robinson LifeSci Advisors, LLC +1 (617) 430-7577 arr@lifesciadvisors.comMedia Contact: Kirsten Thomas The Ruth Group +1 (508) 280-6592 kthomas@theruthgroup.com
- 08/03/2020
|
Can Bionano Genomics Stock Soar 100%? 5-Star Analyst Thinks So
- Until recently, shares of Bionano Genomics (BNGO) had been on an almost constant downward trend, declining by 90% since August 2018. However, sentiment appears to have improved as evidenced by a gain of 50% over the past month.According to Oppenheimer analyst Kevin DeGeeter, there’s still a long way up from here. The 5-star analyst reiterated an Outperform (i.e. Buy) rating on BNGO shares along with a $1.50 price target. The implication for investors? Mighty upside potential of a further 100%. (To watch DeGeeter’s track record, click here)For starters, the heart of the bullish case for Bionano is its role in cytogenetics - the study of chromosomal structures - and in particular, the part its genome imaging system, Saphyr, can play.The instrument is being adopted in the EU, where cytogenetics is “building toward a tipping point.” Labs in Germany, the Netherlands and Italy are “completing validation studies for cytogenetics,” which should lead to further adoption of Saphyr in other labs in each country. Furthermore, a recent study published by a European consortium praised the instrument’s ease of use, efficacy and ability to cut costs, comparing the platform to “ultra-high resolution karyotype (~10,000x) that offers a fast (3–4 days) and cost effective (~$450 list price per genome) alternative to combination of karyotyping and microarrays.”DeGeeter, though, is most excited about an upcoming publication of a US study, which could turn out to be a major catalyst for the stock.“We expect results from the first large validation cohort of US cytogenetics patients to be published in the coming weeks. While US cytogenetics commercial adoption appears slower than we have forecast, due in part to impact of COVID-19, we expect the publication from a consortium led by Brynn Levy at Columbia to be an important milestone supporting future US adoption,” the 5-star analyst said.Over the past three months, 2 other analysts have published reviews of the biotech’s prospects, both concluding Bionano is a Buy. BNGO's Strong Buy consensus rating is backed by a $1.47 average price target, implying potential upside of 97% from current levels. (See BNGO stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
- 07/30/2020
|
Bionano Genome Imaging Provides Essential Scaffolding Results in High Profile Bat Genome Study
- Six reference-quality bat genomes described in a publication in Nature reveal how bats can carry and yet survive deadly virusesSAN DIEGO, July 29, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that a study published in the journal Nature (Jebb, D., Huang, Z., Pippel, M. et al. Six reference-quality genomes reveal evolution of bat adaptations. Nature 583, 578–584 (2020)) used Bionano’s genome imaging technology to build reference-quality genomes of six bat species. The genomes provide evidence that bats can tolerate and survive viral infections much better than other mammals, a trait that is highly relevant in the context of the COVID-19 pandemic. The study was performed as part of the Bat1K global genome consortium in coordination with the Vertebrate Genome Project (VGP). Bionano’s Saphyr genome imaging system played a key role in constructing the genome assemblies that were studied to understand how bats can carry deadly viruses and yet be unaffected by them. The high quality reference genomes were built by combining sequencing with Bionano data, where Bionano data provided the ground truth for the genome structure and was used as the gold standard for reference genome assembly here as well as in many other recent reference genomes. The team compared these bat genomes against the genomes of 42 other mammals to search for genetic differences between bats and other mammals. They identified genes that were lost or amplified throughout bat evolution, including a series of genes involved in echolocation and immune-related genes, that can help explain bats’ ability to tolerate viral infections. Evidence of many viral infections were found in the genomes as well, in the form of viral genome sequences that were permanently integrated into the bat genome. These reference-quality bat genomes provide the basis for continued research on mechanisms of viral infections across species, such as bats to humans, and for the study of differences in virulence between viruses.Erik Holmlin, PhD, CEO of Bionano Genomics commented: “Bats are fascinating mammals with some unusual characteristics, but it is their unique role as a reservoir for many viruses that has put these animals in the spotlight. We are proud that the Vertebrate Genome Project and the Bat1K project used Saphyr genome imaging data as the main scaffolding tool to build accurate platinum genomes. Through its contribution to our understanding of the bat immune system, Bionano’s genomic data continues to contribute to our knowledge of SARS-CoV-2 and the COVID-19 pandemic.”About Bionano GenomicsBionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing. Bionano’s Saphyr system is a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. The Saphyr system is comprised of an instrument, chip consumables, reagents and a suite of data analysis tools, and genome analysis services to provide access to data generated by the Saphyr system for researchers who prefer not to adopt the Saphyr system in their labs. For more information, visit www.bionanogenomics.com.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the potential ability to understand bat’s ability to tolerate viral infections; and Bionano’s contribution to understandings of the bat immune system and broader knowledge regarding COVID-19. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive products; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the loss of key members of management and our commercial team; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2019 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.CONTACTS Company Contact: Erik Holmlin, CEO Bionano Genomics, Inc. +1 (858) 888-7610 eholmlin@bionanogenomics.com Investor Relations Contact: Ashley R. Robinson LifeSci Advisors, LLC +1 (617) 430-7577 arr@lifesciadvisors.com Media Contact: Kirsten Thomas The Ruth Group +1 (508) 280-6592 kthomas@theruthgroup.com
- 07/29/2020
|
BioNano Genomics (BNGO) Receives a Buy from Oppenheimer - Markets
- Oppenheimer analyst Kevin DeGeeter maintained a Buy rating on BioNano Genomics (BNGO – Research Report) today and set a price
- 07/27/2020
|
Bionano Genomics Has Upside Potential In The Stock Price
- Bionano Genomics, Inc. operates in the genome analysis industry.
- 07/24/2020
|
The COVID-19 Host Genome Structural Variant Consortium Formed by Dr. Ravindra Kolhe at Augusta University Creates a Massive Expansion in the Scope of COVID-19 Susceptibility Research with Bionano Genome Imaging
- * Saphyr’s extremely sensitive structural variation detection technology will be used to analyze samples from COVID patients from dozens of clinical sites throughout North America and Europe * Initial target for recruitment is 1,000 patients * The consortium includes more than 40 world-renowned scientists and institutionsSAN DIEGO, July 24, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that a recently formed international consortium of clinical and research sites is using its Saphyr genome imaging system to identify genomic variants that influence resistance or sensitivity to the SARS-CoV2 virus, or COVID-19 disease progression and drug response. The consortium is comparing the genome structures of those patients who show no or mild symptoms and those who show severe illness, while controlling for the known risk factors of age and chronic illness such as asthma, heart disease, diabetes, or other immune-compromising disease. The team plans to analyze at least 1,000 patient genomes with Saphyr.The consortium was founded by Dr. Ravindra Kolhe, the Vice-Chair of Pathology and Section Chief of Molecular and Genetic Pathology at Augusta University and Dr. Alka Chaubey, Scientific Director for the Georgia Esoteric & Molecular Lab at Augusta University. Additionally, it consists of co-investigators from Baylor College of Medicine, Boston’s Children's Hospital of Harvard University, Children’s National Medical Center, Columbia University, George Mason University, MD Anderson Cancer Center, the National Cancer Institute, Oregon Health and Science University, Rockefeller University, San Francisco State University, Sanford Burnham Prebys, UC San Diego, UC Santa Cruz, and Virginia Commonwealth University, with many more in the process of joining.A number of companies have committed to supporting this effort as part of a global Tech Against Covid initiative. Rescale, the High-Performance Computing cloud platform fully integrated with Saphyr, and Amazon, a leading provider of on-demand cloud computing, are donating compute time for the Bionano data analysis. Genoox, the platform for annotation and classification of genomic variants, is donating its compute resources to analyze available sequencing data combined with Bionano’s structural variation calls for an integrated analysis of small and large genomic variants.Initial unpublished findings from the first 30 patients that have been analyzed show that Saphyr detects large amounts of structural variation in many putatively relevant genes, demonstrating that point mutations alone are unlikely to explain disease differences between patients. Bionano’s Saphyr system is expected to provide the crucial structural variation data needed for a full understanding of genome structure in patients.Dr. Ravindra Kolhe, founder of the consortium commented: “We strongly believe that Bionano’s Saphyr platform is uniquely capable of identifying variants that play an important role in regulating COVID-19 in patients, and may be able to explain some of the extreme variation in disease severity and progression that we see in patients. Other studies of the host genome are based on short-read sequencing or SNP-microarrays, and those technologies are unable to detect and account for the large amounts of structural variation that’s present in clinically important regions of the genome. We are hopeful that our initial results will translate into discoveries that truly advance our understanding of this devastating disease, and will improve our ability to treat the sickest patients.”Erik Holmlin, PhD, CEO of Bionano Genomics commented: “The COVID-19 Host Genome Structural Variation Consortium is an important expansion of Bionano’s efforts to help the scientific and medical community in the development of novel, targeted, antiviral therapies or vaccines. We believe that Bionano’s genome imaging technology is the only technology capable of detecting the structural variants that could protect against or predispose patients to the viral infection and influence the severity of the disease. We are thrilled that our technology is being used in a global effort to help bring this pandemic to a halt.”About Bionano Genomics Bionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing. Bionano’s Saphyr system is a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. The Saphyr system is comprised of an instrument, chip consumables, reagents and a suite of data analysis tools, and genome analysis services to provide access to data generated by the Saphyr system for researchers who prefer not to adopt the Saphyr system in their labs. For more information, visit www.bionanogenomics.com.Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: planned scope of the consortium’s research; preliminary findings regarding COVID-19 through the use of Saphyr; and Saphyr’s ability to contribute to research and treatment of COVID-19, including discoveries that can advance an understanding of COVID-19 and improve the ability to treat patients. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive products; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the loss of key members of management and our commercial team; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2019 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.CONTACTS Company Contact: Erik Holmlin, CEO Bionano Genomics, Inc. +1 (858) 888-7610 eholmlin@bionanogenomics.comInvestor Relations Contact: Ashley R. Robinson LifeSci Advisors, LLC +1 (617) 430-7577 arr@lifesciadvisors.comMedia Contact: Kirsten Thomas The Ruth Group +1 (508) 280-6592 kthomas@theruthgroup.com
- 07/24/2020
|
BioNano Genomics (BNGO) Receives Bullish Praise From a Wall Street Pro
- BioNano Genomics (BNGO) shares have been on a tear this month. The stock price of this life sciences instrumentation company has raced ahead 52%, leaving the iShares Nasdaq Biotechnology ETF (IBB) in its dust. But would you believe it has even further to run? Would you believe it could go up another 155%? Maxim's 5-star analyst Jason McCarthy does.The stock has been making moves after new data published by an international consortium showed extremely promising results for one of the company products.In a study of 85 patients with inherited genetic disorders, Bionano’s genome imaging instrument Saphyr identified all 100 chromosomal aberrations in patients’ samples, and therefore equaling cytogenetics standard-of-care tests such as karyotyping, FISH, and/or chromosomal microarray.Why is this important? McCarthy explained: “Considering that the aberrations required a combination of all three methods to complete, Saphyr being able to match the results in 100% of cases with a simplified automated workflow further highlights Saphyr as a disruptive technology in the cytogenetics space.”McCarthy argues Saphyr could be a “game changer” in the emerging digital cytogenetics space. Labor intensive methods are normally required by cytogenetic labs in order to detect and diagnose SV (structural variation) driven diseases. Additionally, these working practices have notable limitations and require a combination of methods to provide “comprehensive characterization.”“Saphyr,” says McCarthy, “Could potentially replace these techniques with a simplified and rapid automated workflow that provides comprehensive detection regardless of the type of variation. Saphyr's workflow is much quicker, running 42 samples in a week… As such, the Saphyr approach could set the stage to integrate into the cytogenetics labs.”To this end, McCarthy rates BNGO a Buy along with a $2 price target. Investors could be pocketing a hefty 155% gain, should McCarthy’s thesis play out in the year ahead. (To watch McCarthy’s track record, click here)With the addition of 2 more Buy ratings posted over the last 3 months, BNGO has a Strong Buy consensus rating. The average price target is $1.47, and while not quite as high as McCarthy’s, could still provide plenty of upside in the shape of 85%. (See BNGO stock-price forecast on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
- 07/23/2020
|
Bionano Genome Imaging Identifies the Most Common Structural Variations Between Individuals with DiGeorge Syndrome
- Nature paper documents largest study of a single genetic disorder using Bionano genome imaging technology to date. Only Bionano’s Saphyr system was capable of resolving this extremely complex genome structure. SAN DIEGO, July 23, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that a study published in the journal Nature used Bionano’s genome imaging technology to establish one of the largest and most structurally accurate sets of genome data for a cohort of affected children and their parents in a study of the most common genomic deletion syndrome, called 22q11.2 Deletion Syndrome (22q11.2DS) or DiGeorge Syndrome.The 22q11.2 Deletion Syndrome (22q11.2DS) is a congenital malformation disorder and the most frequent microdeletion syndrome in humans, with a prevalence of about one in every 3,000 live births and one in every 1,000 pregnancies. Affected patients suffer from such medical issues as congenital cardiac defects, immune deficiencies, speech/language defects, intellectual disabilities, and an increased risk for developing schizophrenia in adolescence or adulthood. The disorder is caused by a de novo deletion of about 3 million base pairs in chromosome 22q11.2, which means that it is not inherited from the parents, but instead occurs uniquely in each individual patient when the large repeats rearrange during cell division. The region of the chromosome where the deletion occurs is highly complex and is known to have many very large duplications.Obtaining structurally accurate pictures of the genomes of patients with DiGeorge Syndrome and their parents is critical to developing a detailed understanding how these mutations form and whether the genomes of the parents harbor any characteristics that would predispose the affected embryo to manifesting the disease causing variant. Despite considerable efforts to date, sequencing technologies have been unable to correctly assemble the 22q11.2 region due to its size, regional complexity, and diversity. In contrast, this paper illustrates that Bionano genome imaging technology allows the characterization of the complex repetitive areas with its unique ability to image extremely long, single DNA molecules.The team, led by scientists from the Children’s Hospital of Philadelphia with contributions from Drexel University and Albert Einstein College of Medicine, analyzed genome structure and variation in 88 individuals from 30 patient families and identified specific genomic arrangements that are the most common in patients and their parents. While no specific patterns could be traced to the parents of affected children, a specific orientation of a ~160,000 base pair sequence module that combined with a ~64,000 inversion was the most frequent disease-causing locus observed in patients. This degree of certainty regarding the presence or absence of any specific patterns in parents, coupled with the findings of common structural variations among affected children is an example of the kind of novel information that only Bionano’s Saphyr system provides.Erik Holmlin, PhD, CEO of Bionano Genomics commented: “The 22q11.2DS study published in Nature demonstrates once again that Bionano’s genome imaging technology is capable of resolving the structure and orientation of the most complex regions of the genome. The single DNA molecules imaged by Saphyr are up to millions of base pairs in length, providing an unambiguous view of the genome that we believe cannot be obtained with short-read or long-read sequencing technologies. We believe Saphyr’s genome imaging technology can facilitate accurate structural analysis at a cost and throughput that enables large studies such as the one published here today. The findings of this study help increase understanding of not just this devastating disease, but several other severe genetic disorders caused by the rearrangement of these extremely large genomic elements. We are proud of the use of Bionano’s technology in this study and the increased understanding which we anticipate will help researchers, clinicians, but also patients and their families.”About Bionano Genomics Bionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing. Bionano’s Saphyr system is a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. The Saphyr system is comprised of an instrument, chip consumables, reagents and a suite of data analysis tools, and genome analysis services to provide access to data generated by the Saphyr system for researchers who prefer not to adopt the Saphyr system in their labs. For more information, visit www.bionanogenomics.com.Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: Saphyr’s capabilities, including its ability to resolve the most complex regions of the genome; the limitations of sequencing technologies; and the benefits of Saphyr’s genome imaging technology and its ability to facilitate large studies. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive products; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the loss of key members of management and our commercial team; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2019 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.CONTACTS Company Contact: Erik Holmlin, CEO Bionano Genomics, Inc. +1 (858) 888-7610 eholmlin@bionanogenomics.comInvestor Relations Contact: Ashley R. Robinson LifeSci Advisors, LLC +1 (617) 430-7577 arr@lifesciadvisors.comMedia Contact: Kirsten Thomas The Ruth Group +1 (508) 280-6592 kthomas@theruthgroup.com
- 07/23/2020
|
Twitter And Discord Are Creating The New 'Boiler Room'
- Twitter and Discord have individuals and groups promoting stocks reminiscent of the ideas portrayed in the older classic movie Boiler Room.
- 07/22/2020
|
Twitter And Discord Are Creating The New 'Boiler Room'
- Twitter and Discord have individuals and groups promoting stocks reminiscent of the ideas portrayed in the older classic movie Boiler Room.
- 07/22/2020
|
BioNano Genomics (BNGO) Receives a New Rating from a Top Analyst - Markets
- Maxim Group analyst Jason McCarthy assigned a Buy rating to BioNano Genomics (BNGO – Research Report) yesterday and set a
- 07/21/2020
|
First Publication from International Consortium Using Bionano Imaging in Genetic Disease Patients Demonstrates that Bionano’s Saphyr Detects All 100 Chromosomal Aberrations in 85 Samples
- First large study in constitutional genetic diseases showed 100% concordance to all gold-standard cytogenetic testing methods combinedDemonstrates Bionano’s continued progress.
- 07/20/2020
|
Maxim Group Thinks BioNano Genomics' Stock is Going to Recover - Markets
- In a report released yesterday, Jason McCarthy from Maxim Group reiterated a Buy rating on BioNano Genomics (BNGO – Research
- 07/18/2020
|
Bionano Genomics Data is Essential Part of the First Ever Complete Assembly of a Human X-Chromosome
- SAN DIEGO, July 16, 2020 -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced that the first ever complete assembly of a human chromosome utilized its genome imaging.
- 07/16/2020
|
Company News for Jul 13, 2020
- Companies in the news are: BNGO, AMRX, ALT, EXPR
- 07/13/2020
|
Bionano Genomics Solidifies its Entry into Solid Tumor Analysis with Launch of New Kit and Protocol that Significantly Simplify Tissue and Solid Tumor Analysis
- SAN DIEGO, July 09, 2020 -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced that it has launched the new Bionano PrepTM SP Tissue and Tumor Kit, a DNA isolation kit.
- 07/09/2020
|
The UK NHS, the Medical College of Wisconsin, and the Leading South Korean Yonsei University Hospital are Among Newest Adopters of Bionano Saphyr® for Digital Cytogenetic Applications
- Bionano Genomics, Inc. (BNGO) announced today that King’s College Hospital London, part of the NHS (National Health Service) in the UK, the Medical College of Wisconsin, and Yonsei University Hospital, the leading South Korean University Hospital, have adopted the Saphyr system. The addition of Saphyr allows their scientists and clinicians to achieve comprehensive analysis of chromosomal aberrations and structural variations, including some that are unresolved by other current technologies, such as chromosomal microarray and next-generation sequencing (NGS) technology.
- 06/26/2020
|
Maxim Group Thinks BioNano Genomics' Stock is Going to Recover - Markets
- In a report released today, Jason McCarthy from Maxim Group maintained a Buy rating on BioNano Genomics (BNGO – Research
- 06/23/2020
|
BioNano Genomics (BNGO) Receives a Buy from Oppenheimer - Markets
- In a report released yesterday, Kevin DeGeeter from Oppenheimer maintained a Buy rating on BioNano Genomics (BNGO – Research Report),
- 06/19/2020
|
The Daily Biotech Pulse: Tiziana Snags A Patent Win, Decision Day For Nabriva And Evoke, IPOs
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 18)
ADC Therapeutics SA (NYSE:...
- 06/19/2020
|
Bionano Genomics, Inc.'s (BNGO) CEO Dr. Erik Holmlin on Q1 2020 Results - Earnings Call Transcript
- Bionano Genomics, Inc. (NASDAQ:BNGO) Q1 2020 Results Earnings Conference Call June 18, 2020, 4:30 PM ET Company Participants Monique Kosse - Investor Relations
- 06/18/2020
|
Bionano Genomics Reports First Quarter 2020 Financial Results and Provides Business Update
- SAN DIEGO, June 18, 2020 -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr®, a platform for ultra-sensitive and.
- 06/18/2020
|
Bionano Announces Amendment to Proxy Statement for Annual Meeting of Stockholders
- Bionano Genomics, Inc. (BNGO) today announced that on June 17, 2020 it filed an amendment to its Proxy Statement for its 2020 Annual Meeting of Stockholders in order to amend and supplement Proposal 1 in the Proxy Statement. Pursuant to Proposal 1, Bionano is submitting to its stockholders for approval a series of alternate amendments to its Amended and Restated Certificate of Incorporation, to effect, at the discretion of the Board of Directors: (i) a reverse split of Bionano’s common stock in the range of 1-for-10 to 1-for-20; and (ii) for such reverse stock split in the range of 1-for-10 to 1-for-20, a reduction in the number of authorized shares of common stock from 200,000,000 to a number ranging from 40,000,000 to 20,000,000 shares, respectively.
- 06/18/2020
|
The Daily Biotech Pulse: Eloxx Resumes Cystic Fibrosis Study, Rexahn's Reverse Merger, Ultragenyx, Epizyme Await FDA Decisions
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 17)
Adverum Biotechnologies Inc...
- 06/18/2020
|
The Week Ahead In Biotech: FDA Decisions In The Cards For Merck, Epizyme, Evoke And Ultragenyx
- Biotech stocks came under pressure along with the broader market in the week ended June 12, as a worsening pandemic situation and its impact on the economy led to an across-the-...
- 06/14/2020
|
Bionano Genomics to Report First Quarter 2020 Financial Results and Host a Conference Call and Webcast on June 18
- SAN DIEGO, June 12, 2020 -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr®, a platform for ultra-sensitive and.
- 06/12/2020
|
Data Presented at European Society of Human Genetics (ESHG) Conference Shows Saphyr System has 100% Concordance with Standard Cytogenetics in Leukemias and Constitutional Aberrations
- Bionano Genomics, Inc. (BNGO) today announced that three top cytogeneticists from leading institutions in The Netherlands and Germany presented data at the 2020 European Society of Human Genetics (ESHG) Virtual Conference showing 100% concordance between the Saphyr system and standard cytogenetic tests. The three separate presentations compared data generated with Bionano’s Saphyr system against gold standard cytogenetic methods consisting of karyotyping, FISH, and/or chromosomal microarray in patients with leukemias and a variety of constitutional or inherited genetic disorders.
- 06/11/2020
|
Bionano Genomics Announces Issuance of US Patent for Combined Nanochannel-Nanopore Device
- Bionano Genomics, Inc. (NASDAQ: BNGO) today announced that the United States Patent and Trademark Office will issue US Patent No. 10,676,352 on June 9th, 2020.
- 06/08/2020
|
What Makes Bionano Genomics, Inc. (BNGO) a New Strong Buy Stock
- Bionano Genomics, Inc. (BNGO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
- 05/28/2020
|
Bionano to Participate in Maxim Group’s Covid-19 Virtual Conference Series: The Role of Cell Therapy and Clarity on Testing
- Bionano Genomics, Inc. (BNGO) today announced that Erik Holmlin, Ph.D., CEO of Bionano, will participate on a panel entitled: “Testing and Susceptibility – Clearing the Air,” during the virtual conference “The Role of Cell Therapy & Clarity on Testing” hosted by Maxim Group and M-Vest today, Wednesday, May 27, 2020. The panel will include an interactive discussion moderated by Dr. Jason McCarthy, Biotechnology Analyst at Maxim. To access the panel discussion, please RSVP at https://m-vest.com/insights/blog/covid-19-virtual-conference.
- 05/27/2020
|
Cancer Genomics Consortium Members Demonstrate 100% Concordance Between Bionano Saphyr and Gold Standard Cytogenetics in Leukemia
- Bionano Genomics, Inc. (BNGO) announced that in an online presentation hosted by the Cancer Genomics Consortium (CGC) on May 12, 2020, Dr. Brynn Levy from Columbia University and Dr. Rashmi Kanagal-Shamanna from the MD Anderson Cancer Center each presented updates on their work showing 100% concordance between Bionano Genomics’ optical mapping technology and current gold standard cytogenetic methods. In his presentation, Dr. Levy reported on a blinded, prospective study comparing the results generated by Bionano’s Saphyr instrument to results from routine clinical testing in CLIA laboratories using current gold standard cytogenetic techniques.
- 05/19/2020
|
Bionano Genomics to Report First Quarter 2020 Financial Results on June 18, 2020
- Bionano Genomics, Inc. (BNGO), a life sciences instrumentation company that develops and markets Saphyr®, a platform for ultra-sensitive and ultra-specific structural variation detection in genome analysis, today announced that the company is relying on the order issued by the U.S. Securities and Exchange Commission to delay the filing of its Quarterly Report on Form 10-Q for the quarter ended March 31, 2020 due to circumstances related to the COVID-19 pandemic. The company plans to file the Form 10-Q and report its financial results for the quarter ended March 31, 2020 on June 18, 2020. In addition, due to uncertainties regarding the duration and impact of the COVID-19 pandemic, the company is suspending any guidance, anticipated timelines or other outlooks previously provided for 2020.
- 05/14/2020
|
Bionano Genomics Adds Healthcare and Genomics Industry Experts with Experience in Commercialization and Reimbursement to Its Board of Directors
- Bionano Genomics, Inc. (BNGO) today announced the appointment of Hannah Mamuszka and Yvonne Linney, PhD, to its board of directors. Junfeng Wang, who originally joined the company’s board as a representative of Legend Capital, a private equity firm that invested in the company before its initial public offering, has resigned as member of the board.
- 05/04/2020
|
Largest North American Site for FSHD Muscular Dystrophy Testing Adopts Bionano Genomics’ Saphyr for Majority of Clinical Tests
- Bionano Genomics, Inc. (BNGO) announced that the University of Iowa Hospitals and Clinics (UIHC) will switch their method of clinical molecular testing for patients with presumed Facioscapulohumeral Muscular Dystrophy (FSHD) to optical mapping using Bionano’s Saphyr System. The UIHC recently completed development of an FSHD assay on Saphyr and validated its results by processing patient samples for FSHD.
- 04/22/2020
|
BofA likes Molina Healthcare in premarket analyst action
- Bionano Genomics (NASDAQ:BNGO) initiated with an Outperform rating and a $1.50 (443% upside) price target at Oppenheimer. Shares up 19% premarket.NovoCure (NASDAQ:NVCR) initiated with an Overweight ra
- 04/08/2020
|
Analysts Offer Insights on Healthcare Companies: BioNano Genomics (BNGO) and PTC Therapeutics (PTCT)
- There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BioNano Genomics (BNGO) and PTC Therapeutics (PTCT) with
- 04/08/2020
|
Analysts Offer Insights on Healthcare Companies: BioNano Genomics (NASDAQ: BNGO) and PTC Therapeutics (NASDAQ: PTCT)
- There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BioNano Genomics
- 04/08/2020
|
The Daily Biotech Pulse: Fate Therapeutics Inks Cell Therapy Deal With J&J, Zentalis IPO
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 2)BELLUS Health Inc (NASDAQ: BLU)Down In The Dumps (Biotech Stocks Hitting 52-week Lows April 2) * BIOLASE Inc (NASDAQ: BIOL) * BioNano Genomics Inc (NASDAQ
- 04/03/2020
|
The Daily Biotech Pulse: Fate Therapeutics Inks Cell Therapy Deal With J&J, Zentalis IPO
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs April 2)
BELLUS Health Inc (NASDAQ:...
- 04/03/2020
|
BIONANO GENOMICS ANNOUNCES PRICING OF $18 MILLION UNDERWRITTEN PUBLIC OFFERING
- BIONANO GENOMICS, INC. (BNGO), a genome analysis company that provides tools and services based on its Saphyr® system to scientists and clinicians conducting genetic research and patient testing, today announced the pricing of an underwritten public offering of 54,546,000 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and common warrants to purchase up to an aggregate of 54,546,000 shares of common stock. Each share of common stock and, as applicable, each pre-funded warrant is being sold together with a common warrant to purchase one share of common stock at a combined effective price to the public of $0.33 per share and accompanying common warrant.
- 04/02/2020
|
Bionano Genomics to Support Largest Study to Date on COVID-19 Disease Susceptibility
- Bionano Genomics, Inc. (BNGO) announced today the launch of the largest study to date aiming to identify genomic variants and novel active substances that influence resistance or sensitivity to the SARS-CoV2 virus, or COVID-19, disease progression and drug response. The study will control for viral strain differences, and for the known risk factors of age and chronic illness such as heart disease, diabetes, or other immune-compromising disease. The first study of this kind is underway in Wuhan, China, and is being performed at the site of Wuhan-based GrandOmics, a service provider using Bionano technology.
- 03/31/2020
|
Three Top European Sites Adopt Bionano Saphyr® for Cancer, Genetics, and Cytogenetic Applications
- Bionano Genomics, Inc. (BNGO) announced today that the following top European institutions have recently incorporated the Saphyr® system into their repertoire of solutions for genome analysis and are now operating them across a range of applications: Curie Institute in Paris, France; NHS Lothian in Edinburgh, Scotland; and MVZ Martinsried in Munich, Germany. The Saphyr system is designed to enable comprehensive analysis of genome structure, including genomic structural variations unresolved by current next-generation sequencing (NGS) technology.
- 03/23/2020
|
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on March 18)
Biomerica, Inc. (NASDAQ...
- 03/19/2020
|
The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 12.)
Masimo...
- 03/13/2020
|
Bionano Genomics Will Be Used in Research Identifying Gene Variants that Contribute to Coronavirus Disease Susceptibility
- Bionano Genomics announced the launch of a global network of studies aiming to identify genomic variants that influence COVID-19 disease resistance, sensitivity, disease progression and drug response. The first study will focus on the Wuhan, China outbreak, and will be performed at the site of Wuhan-based Bionano service provider GrandOmics in collaboration with Bionano Genomics. At least one hundred patients who tested positive for COVID-19 infection will undergo whole genome analysis using the Bionano Saphyr system, and genomic variants will be compared between those patients who show no or mild symptoms and those who show severe illness.
- 03/10/2020
|
CY, VALE among premarket losers
- TransEnterix (NYSEMKT:TRXC) -57% after pricing equity offering.American Outdoor Brands (NASDAQ:AOBC) -26% as coronavirus impact weighs and Q4 earnings.Bionano Genomics (NASDAQ:BNGO) -23% on Q4 earning
- 03/06/2020
|
The Daily Biotech Pulse: Breakthrough Device Designation For Neuronetics, AbbVie Receives European Label Expansion, AstraZeneca Flunks Late-Stage Study
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit hit 52-week highs March 5.) * Arcus Biosciences Inc (NYSE: RCUS) * Arcturus Therapeutics Ltd (NASDAQ: ARCT) * BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) * Centogene NV
- 03/06/2020
|
7 Stocks Moving In Thursday's After-Hours Session
- Gainers
Okta (NASDAQ: OKTA) shares are trading higher after the company reported better-than-expected Q4 EPS and sales results. The company issued Q1 and FY21 sales guidance...
- 03/05/2020
|
Bionano Genomics Reports Fourth Quarter and Year End 2019 Financial Results and Provides Business Update
- SAN DIEGO, March 05, 2020 -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr®, a platform for ultra-sensitive.
- 03/05/2020
|
The Daily Biotech Pulse: Trevana Pain Drug Resubmission Accepted For Review, Can-Fite To Explore Treatment For COVID-19
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 4) * 89bio Inc (NASDAQ: ETNB) * Arcus Biosciences Inc (NYSE: RCUS) * Arcturus Therapeutics Ltd (NASDAQ: ARCT)(announced a partnership with Duke-NUS
- 03/05/2020
|
Healthcare dominates premarket losers amidst coronavirus situation
- Spherix (NASDAQ:SPEX) -25%.Dynatronics (NASDAQ:DYNT) -22%.China Pharma Holdings (NYSEMKT:CPHI) -19%.Co-Diagnostics (NASDAQ:CODX) -17%.Tilray (NASDAQ:TLRY) -14% on Q4 earnings.Cleveland BioLabs (NASDAQ
- 03/03/2020
|
Bionano Genomics to Report Fourth Quarter and Year End 2019 Financial Results and Host a Conference Call and Webcast on March 5
- SAN DIEGO, Feb. 28, 2020 -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr®, a platform for ultra-sensitive and.
- 02/28/2020
|
Bionano Genomics Releases Saphyr Updates for Industry-Leading Data Yields that Enable Analysis of Complex Cancer Samples at Unprecedented Depths
- Bionano Genomics (BNGO) today announced updates to the Saphyr® System designed to increase the speed of data collection, simplify sample preparation for solid tumors and animal tissue and significantly improve the total data yield per flow cell, allowing for a complete workflow for the in-depth analysis of complex, heterogeneous cancer samples. Bionano is also introducing two new ways for customers to access Bionano data: the first, by offering a competitively priced service for human genome analysis, and the second, a reagent-rental model that provide scientists and labs with the Saphyr system when they make a certain minimum commitment to purchase Bionano consumables. As a result of the updates announced today, Saphyr can collect as much as 5 Terabasepairs of data, or over 1500x coverage of a human genome, in 48 to 96 hours on three samples in parallel, for a total of 15 Tbp on a single Saphyr Chip.
- 02/24/2020
|
Bionano Genomics Data Drives Scientific Discoveries in Solid Tumors and Leukemias, To Be Presented at the 2020 AGBT Conference
- Bionano Genomics, Inc. (BNGO), a life sciences instrumentation company that develops and markets Saphyr®, a platform for ultra-sensitive and ultra-specific structural variation detection in genome analysis, announced today that cancer, genetic disease and genomics researchers using the Saphyr system will present their results at the Advances in Genome Biology and Technology (AGBT) Conference taking place February 23 – 26 in Marco Island, Florida. The impact of Saphyr for genome-wide detection of structural variation will be highlighted at AGBT with a total of 19 oral and poster presentations and talks hosted by Bionano.
- 02/21/2020
|
TSLA, INO among premarket gainers
- vTv Therapeutics (NASDAQ:VTVT) +80% on positive TTP399 data.Taubman Centers (NYSE:TCO) +52% on being acquired by Simon Property Group.Edgewell Personal Care (NYSE:EPC) +21% after Q4 results.Mereo BioP
- 02/10/2020
|
Bionano Genome Imaging Concordant with Traditional Cytogenetics in Landmark Leukemia Study
- Bionano Genomics, Inc. (BNGO) announced today that a team led by Dr. Alexander Hoischen from Radboud University Medical Center (RUMC) in the Netherlands reported the results of a successful validation study comparing the performance of Bionano Genomics’ Saphyr® system to traditional cytogenetic methods for the clinical analysis of leukemia genomes. The study, published in bioRxiv, found that Saphyr was 100% concordant with the standard of care for the detection of somatic chromosomal abnormalities. In a diagnostic set-up, especially for hematological malignancies, the comprehensive analysis of all cytogenetic aberrations requires a combination of techniques, such as karyotyping, fluorescence in situ hybridization and CNV-microarrays.
- 02/10/2020
|
Users of Bionano Genomics’ Saphyr System to Present Reference Genome Assembly and SV Discovery for Plant and Animal Genomes at the PAG XXVIII Conference
- SAN DIEGO, Jan. 10, 2020 -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr®, a platform for ultra-sensitive and.
- 01/10/2020
|
Bionano Genomics’ Saphyr® System is Adopted by GeneDx for the Clinical Detection of Genetic Variants in Muscular Dystrophies, Developmental and Reproductive Disorders
- Bionano Genomics, Inc. (BNGO), a life sciences instrumentation company that develops and markets the Saphyr® System, a genome imaging platform for ultra-sensitive and ultra-specific genome-wide structural variation detection, today announced the adoption of Saphyr by GeneDx, Inc., to develop assays that will transition to their clinical laboratory in Gaithersburg, MD. Assays based on the Bionano optical mapping technology will complement GeneDx’s current testing methodologies.
- 01/06/2020
|
Bionano Genomics Stock on Offer in IPO
- If you've been an Illumina (ILMN) investor for a while, you have to be stoked about how well your investment has performed. This is a company that has an 80% market share selling machines that are the 'picks and shovels' of the growing genomics market. More than half of the company's revenues come from 'consumables', in other words, they don't just make money selling their sequencing machines but also from recurring revenues once the machines are sold. And they're selling like hotcakes: Consequently, investors have increasingly high expectations of future performance based on how much shares have soared over the past years. Check
- 07/15/2018
|
